IMAX (IMAX) 10-Q 20 Oct 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2016shares
Document and Entity Information [Abstract]
Entity Registrant Name	IMAX Corporation
Entity Central Index Key	921,582
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	Yes
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock Shares Outstanding	66,813,963
Trading Symbol	IMAX

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 218,104	$ 317,449
Accounts receivable, net of allowance for doubtful accounts of $1,026 (December 31, 2015 - $1,146)	89,247	97,981
Financing receivables	118,897	117,231
Inventories	51,015	38,753
Prepaid expenses	11,603	6,498
Film assets	15,165	14,571
Property, plant and equipment	233,984	218,267
Other assets	26,419	26,136
Deferred income taxes	26,233	26,666
Other intangible assets	29,605	28,950
Goodwill	39,027	39,027
Total assets	859,299	931,529
Liabilities
Bank indebtedness	27,806	29,276
Accounts payable	16,733	23,455
Accrued and other liabilities	90,485	95,748
Deferred revenue	97,220	104,993
Total liabilities	232,244	253,472
Commitments and contingencies
Non-controlling interests
Non-controlling interests	2,693	3,307
Shareholders' equity
Capital stock common shares - no par value. Authorized - unlimited number. 66,813,963 - issued and 66,813,787 outstanding (December 31, 2015 - 69,673,244 - issued and outstanding)	435,829	448,310
Less: Treasury stock held in trust, 176 shares at cost	(6)	0
Other equity	180,358	168,425
Accumulated (deficit) earnings	(43,816)	15,499
Accumulated other comprehensive loss	(4,562)	(7,443)
Total shareholders' equity attributable to common shareholders	567,803	624,791
Non-controlling interests	56,559	49,959
Total shareholders' equity	624,362	674,750
Total liabilities and shareholders' equity	$ 859,299	$ 931,529

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Assets
Allowance for doubtful accounts	$ 1,026	$ 1,146
Shareholders' equity
Common stock, shares issued	66,813,963	69,673,244
Common stock, shares outstanding	66,813,787	69,673,244
Number of treasury shares held in trust for future settlement of share based awards	176

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues
Equipment and product sales	$ 30,835	$ 33,083	$ 81,064	$ 72,824
Services	37,195	33,024	122,853	115,698
Rentals	16,007	16,665	58,538	59,006
Finance income	2,288	2,329	6,991	6,803
Other	225	0	975	141
Revenues, total	86,550	85,101	270,421	254,472
Costs and expenses applicable to revenues
Equipment and product sales	15,690	21,949	49,075	43,010
Services	20,393	15,899	58,517	50,201
Rentals	5,504	4,864	15,367	13,856
Other	64	0	110	0
Cost and expenses applicable to revenues, total	41,651	42,712	123,069	107,067
Gross margin	44,899	42,389	147,352	147,405
Selling, general and administrative expenses (including share-based compensation expense of $7.7 million and $22.5 million for the three and nine months ended September 30, 2016, respectively (2015 - expense of $4.3 million and $14.9 million, respectively))	30,686	24,973	92,706	82,348
Research and development	4,460	2,722	11,603	9,611
Amortization of intangibles	531	429	1,537	1,302
Receivable provisions, net of recoveries	275	361	631	709
Asset impairments	1,223	245	1,223	245
Impairment of investments	0	0	194	350
Income from operations	7,724	13,659	39,458	52,840
Interest income	370	222	1,217	727
Interest expense	(469)	(463)	(1,325)	(1,170)
Income from operations before income taxes	7,625	13,418	39,350	52,397
Provision for income taxes	(2,551)	(2,477)	(9,635)	(12,408)
Loss from equity-accounted investments, net of tax	(690)	(427)	(2,471)	(1,610)
Net income	4,384	10,514	27,244	38,379
Less: Net income attributable to non-controlling interests	(1,859)	(1,904)	(7,401)	(5,028)
Net income attributable to common shareholders	$ 2,525	$ 8,610	$ 19,843	$ 33,351
Net income per share attributable to common shareholders - basic and diluted:
Net income per share - basic	$ 0.04	$ 0.12	$ 0.29	$ 0.47
Net income per share - diluted	$ 0.04	$ 0.12	$ 0.29	$ 0.46

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statements of Operations [Abstract]
Share-based compensation costs	$ 7.7	$ 4.3	$ 22.5	$ 14.9

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net income	$ 4,384	$ 10,514	$ 27,244	$ 38,379
Unrealized net (loss) gain from cash flow hedging instruments	(293)	(2,309)	1,865	(4,983)
Realization of cash flow hedging net loss upon settlement	572	1,045	2,565	2,196
Foreign currency translation adjustments	(452)	(992)	(1,849)	(1,162)
Amortization of postretirement benefit plan actuarial loss	17	0	51	0
Other comprehensive (loss) income, before tax	(156)	(2,256)	2,632	(3,949)
Income tax (expense) benefit related to other comprehensive (loss) income	(77)	558	(1,166)	996
Other comprehensive (loss) income, net of tax	(233)	(1,698)	1,466	(2,953)
Comprehensive income	4,151	8,816	28,710	35,426
Less: Comprehensive income attributable to non-controlling interests	(1,717)	(2,056)	(5,986)	(5,192)
Comprehensive income attributable to common shareholders	$ 2,434	$ 6,760	$ 22,724	$ 30,234

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating Activities
Net income	$ 27,244	$ 38,379
Adjustments to reconcile net income to cash from operations:
Depreciation and amortization	34,179	31,191
Write-downs, net of recoveries	2,903	2,928
Change in deferred income taxes	(517)	5,097
Stock and other non-cash compensation	22,896	15,204
Unrealized foreign currency exchange (gain) loss	(206)	716
Loss from equity-accounted investments	2,769	2,756
Gain on non-cash contribution to equity-accounted investees	(298)	(1,146)
Investment in film assets	(14,162)	(12,069)
Changes in other non-cash operating assets and liabilities	(29,504)	(41,033)
Net cash provided by operating activities	45,304	42,023
Investing Activities
Purchase of property, plant and equipment	(10,033)	(38,443)
Investment in joint revenue sharing equipment	(25,524)	(20,969)
Investment in new business ventures	0	(2,000)
Acquisition of other intangible assets	(2,931)	(3,622)
Net cash used in investing activities	(38,488)	(65,034)
Financing Activities
Increase in bank indebtedness	0	17,568
Repayment of bank indebtedness	(1,500)	0
Repurchase of common shares	(100,378)	(34,279)
Settlement of restricted share units and options	(8,376)	(7,859)
Common shares issued - stock options exercised	7,196	23,838
Taxes paid on secondary sale and repatriation dividend	(2,991)	0
Taxes withheld and paid on employee stock awards vested	(230)	(223)
Treasury stock purchased for future settlement of restricted share units	(6)	(2,141)
Credit facility amendment fees paid	0	(1,310)
Issuance of subsidiary shares to non-controlling interests - private offering	0	40,000
Share issuance costs from the issuance of subsidiary shares to non-controlling interests - private offering	0	(2,000)
Net cash (used in) provided by financing activities	(106,285)	33,594
Effects of exchange rate changes on cash	124	275
(Decrease) increase in cash and cash equivalents during period	(99,345)	10,858
Cash and cash equivalents, beginning of period	317,449	106,503
Cash and cash equivalents, end of period	$ 218,104	$ 117,361

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Basis of Presentation and Condensed Consolidated Statements of Operations Supplemental Information [Abstract]
Basis of Presentation	1. Basis of Presentation IMAX Corporation, together with its consolidated subsidiaries (the “Company”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which the Company has identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. The nature of the Company’s business is such that the results of operations for the interim periods presented are not necessarily indicative of results to be expected for the fiscal year. In the opinion of management, the information contained herein reflects all normal and recurring adjustments necessary to make the re sults of operations for the interim periods a fair statement of such operations. The Company has evaluated its various variable interests to determine whether they are VIEs as required by the Consolidation Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC” or “Codification”). The Company has 11 film production companies that are VIEs. For five of the Company’s film production companies, the Company has determined that it is the primary beneficiary of these entities as the Company has the power to direct the activities of the respective VIE that most significantly impact the respective VIE’s economic performance and has the obligation to absorb losses of the VIE that could potentially be significant to the re spective VIE or the right to receive benefits from the respective VIE that could potentially be significant to the respective VIE. These consolidated production companies have total assets of $ 8.4 million (December 31, 2015 — $ 7.2 million) and total liabilities of $ 4.1 million as at September 30, 2016 (December 3 1, 2015 — $ 4.1 million). The majority of these consolidated assets are held by the IMAX Original Film Fund (the “Film Fund”) as described in note 16(b). For the other six film production companies which are VIEs, the Company did not consolidate these film entities since it does not have the power to direct activities and does not absorb the majority of the expected losses or expected residual returns. The Company equity accounts for these entities. As at September 30, 2016 , these six VIEs have total assets of $ 0.4 million (December 31, 2015 — $ 0.4 million) and total liabilities of $ 0.4 million (December 31, 2015 — $ 0.4 million). Earnings of the investees included in the Company’s condensed consolidated statemen t s of operations amounted to $nil and $nil for the three and nine months ended September 30, 2016 , respectively ( 2015 — $nil and $nil, respectively ). The carrying value of these investments in VIEs that are not consolidated is $nil at September 30, 2016 (December 31, 2015 — $nil). A loss in value of an inves tment other than a temporary decline is recognized as a charge to the condensed consolidated statement s of operations. The Company’s exposure, which is determined based on the level of funding contributed by the Company and the development stage of the resp ective film, is $nil at September 30, 2016 (December 31, 2015 — $nil). The Company accounts for investments in new business ventures using the guidance of the F ASB ASC 323 “Investments – Equity Method and Joint Ventures” (“ASC 323”) or ASC 320 “Investments in Debt and Equity Securities” (“ASC 320”), as appropriate. All intercompany accounts and transactions, including all unrealized intercompany profits on trans actions with equity-accounted investees, have been eliminated. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. These interim financial state ments should be read in conjunction with the consolidated financial statements included in the Company’s 2015 Annual Report on Form 10-K for the year ended December 31, 2015 (“the 2015 Fo rm 10-K”) which should be consulted for a summary of the significant accounting policies utilized by the Company. These interim financial statements are prepared following accounting policies consistent with the Company’s financial statements for the year ended December 31, 2015 , except as noted below.

New Accounting Standards and Ac

New Accounting Standards and Accounting Changes	9 Months Ended
	Sep. 30, 2016
New Accounting Standards and Accounting Changes [Abstract]
New Accounting Standards and Accounting Changes	2. New Accounting Standards and Accounting Changes Adoption of New Accounting Policies In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” (“ASU 2015-01”). Prior to the changes under ASU 2015-01, an entity was required to separately classify, present and disclose extraordinary events and transactions under the disclosure requirements of Subtopic 225-20, “Income Statement – Extraordinary and Unusual Items” (“Subtopic 225-20”). ASU 2015-01 eliminates from U.S. GAAP the concept of extraordinary items therefore such separate disclosure is no longer require d in the Income Statement of an entity. For public companies, the amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments can be applied prospectively or retrospectively. T he Company prospectively adopted the amendments under ASU 2015-01 on January 1, 2016. The adoption of the standard did not have an impact on the disclosures presented in the condensed consolidated statement s of operations for the three and nine months ende d September 30, 2016 and 2015, respectively. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis ” (“ASU 2015-02”). ASU 2015-02 changes the analysis that a reporting entity must perform t o determine whether it should consolidate certain types of legal entities such as limited partnerships and similar entities, and variable interest entities that have free arrangements and related party relationships. Furthermore, all legal entities are su bject to re-evaluation under the revised consolidation model. The amendments also provide a scope exception from consolidation guidance for reporting entities with interest s in legal entities that are required to comply with or operate in accordance with r equirements that are similar to those in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds. For public companies, the amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments can be applied retrospectively or using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The Company adopted the amendments under A SU 2015-02 retrospectively on January 1, 2016. The adoption of the standard did not have an impact on the Company’s condensed consolidated financial statements as there was no change to the entities currently consolidated by the Company. In April 2015, th e FASB issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”), and in August 2015 issued ASU No. 2015-15, “Interest – Imputation of Interest (Subtopic 835-30): Pres entation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements” (“ASU 2015-15”). Under ASU 2015-03, debt issuance costs reported on the balance sheet will be reflected as a direct deduction from the related debt liab ility rather than as an asset. While ASU 2015-03 addresses costs related to term debt, ASU 2015-15 provides clarification regarding costs to secure revolving lines of credit, which are, at the outset, not associated with an outstanding borrowing. ASU 2015- 15 provides commentary that the U.S Securities and Exchange Commission (“SEC”) staff would not object to an entity deferring and presenting costs associated with line-of-credit arrangements as an asset and subsequently amortizing them ratably over the term of the revolving debt arrangement. For public companies, the amendments apply to annual periods beginning on or after December 15, 2015, and interim periods within those years and are to be applied retrospectively. The Company adopted these standards on J anuary 1, 2016. As at December 31, 2015, $0.4 million of unamortized debt issuance costs related to the Company’s loan to finance the construction of its Playa Vista facility were reclassified in the condensed consolidated balance sheet from Other assets t o Bank indebtedness. The Company will continue to defer and present the debt issuance cost related to its senior secured revolving credit facility in Other assets and amortize it ratably over the term of the agreement. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after Decemb er 15, 2016. ASU 2016-09 requires that the Company elect to account for forfeitures based on an estimate of the number of awards for which the requisite service period will not be rendered or to account for forfeitures as they occur. The Company elected to early adopt ASU 2016-09 during the second quarter of 2016 and to account for forfeitures as they occur. The impact from the adoption of the provisions related to forfeiture rates was reflected in the Company’s condensed consolidated financial statements o n a modified retrospective basis resulting in a balance sheet reclass of $4.4 million decrease to Accumulated earnings, $0.9 million increase to Deferred income taxes and $5.3 million increas e to Other equity. A recovery of stock-based compensation expense of $2.7 million for the nine month period ended September 30, 2016 was also recorded. Amendments related to accounting for excess tax benefits have been adopted prospectively resulting in a tax benefit of $0.1 million for the nine months ended September 3 0, 2016, and amendments related to the condensed consolidated statement of cash flows have been adopted retrospectively. See Notes 11 and 12 for further discussion of the impact on the Company’s condensed consolidated financial statements from the adoption of ASU 2016-09. Recently Issued FASB Accounting Standard Codification Updates In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 20 16-01”). The purpose of the amendment is intended to provide users of financial statements with more useful information on the recognition, measurement, presentation, and disclosure of financial instruments. For public entities, the amendments in ASU 2016- 01 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-01 on its condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-0 2, “Leases (Topic 842)” (“ASU 2016-02”). The purpose of the amendment is to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. New disclosures will include qualitative and quantitative requirements to provide additional information about the amounts recorded in the financial statements. Lessor accounting will remain largely unchanged from current guidance, however ASU 2016-02 will provide improvements that are intended to align lessor accounting with the lessee model and with updated revenue recognition guidance. For public entities, the amendments in ASU 2016-02 are effective for interim and annual reporting periods beginning after December 15, 2018. The Company is curr ently assessing the impact of ASU 2016-02 on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relati onships” (“ASU 2016-05”). The amendments in ASU 2016-05 apply to all reporting entities for which there is a change in the counterparty to a derivative instrument that has been designated as a hedging instrument under Topic 815. The amendments clarify that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require de-designation of that hedging relationship provided that all other hedge accounting criteria (i ncluding those in paragraphs 815-20-35-14 through 35-18) continue to be met. For public entities, the amendments in ASU 2016-05 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU 2016-05 on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-07, “Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting” (“ASU 20 16-07”). The purpose of the amendment is to eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investmen t, results of operations, and retained earnings retroactively on a step-by step basis as if the equity method had been in effect during all previous periods that the investment had been held. For public entities, the amendments in ASU 2016-07 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU 2016-07 on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Con tracts with Customers (Topic 606): Principal versus Agent Considerations” (“ASU 2016-08”). The purpose of ASU 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. For public entities, the amendments in ASU 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-08 on its condensed consolidated financial statements. In April 2016, the FASB issued ASU No. 2016-10, “Rev enue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The purpose of ASU 2016-10 is to provide more detailed guidance in the following key areas: identifying performance obligations and licenses of intellectual property. For public entities, the amendments in ASU 2016-10 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-10 on its condensed consolidat ed financial statements. In May 2016, the FASB issued ASU No. 2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 pursuant to Staff announcements at the March 3, 2016 EITF Meeting” (“ASU 2016-11”). The purpose of ASU 2016-11 is to rescind from the FASB Accounting Standards Codification certain SEC paragraphs as a result of two SEC Staff Announcements at the March 3, 2016 meeting. For p ublic entities, the amendments in ASU 2016-11 related to Topic 605 are effective for interim and annual reporting periods beginning after December 15, 2017 and amendments related to Topic 815 are effective for interim and annual reporting periods beginning after December 15, 2015. The Company is currently assessing the impact of ASU 2016-11 related to topic 605 on its condensed consolidated financial statements. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 66 0): Narrow-Scope Improvements and Practical Expedients” (“ASU 2016-12”). The purpose of ASU 2016-12 is to clarify certain narrow aspects of Topic 66 0 such as assessing the collecti bility criterion, presentation of sales taxes and other similar taxes collec ted from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical correction. For public entities, the amendments in ASU 2016-12 are effective for interim and annual reporting periods beginnin g after December 15, 2017. The Company is currently assessing the impact of ASU 2016-12 on its condensed consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The purpose of ASU 2016-13 is to require a financial asset measured on the amortized cost basis to be presented at the net amount expected to be collected. Credit losses relating to available-for-sale de bt securities should be recorded through an allowance for credit losses. For public entities, the amendments in ASU 2016-13 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the imp act of ASU 2016-13 on its condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The purpose of ASU 20 16-15 is to reduce the diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. For public entities, the amendments in ASU 2016-15 are effective for interim and annual reporting perio ds beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-15 on its condensed consolidated financial statements. Recently issued FASB accounting standard codification updates, except for the above noted standards, we re not material to the Company’s condensed consolidated financial statements for the period ended September 30, 2016 .

Financing Receivables

Financing Receivables	9 Months Ended
	Sep. 30, 2016
Financing Receivables [Abstract]
Financing Receivables	3. Financing Receivables Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales of theater systems are as follows: September 30, December 31, 2016 2015 Gross minimum lease payments receivable $ 11,341 $ 13,998 Unearned finance income (1,826) (2,381) Minimum lease payments receivable 9,515 11,617 Accumulated allowance for uncollectible amounts (672) (672) Net investment in leases 8,843 10,945 Gross financed sales receivables 148,358 146,232 Unearned finance income (37,661) (39,378) Financed sales receivables 110,697 106,854 Accumulated allowance for uncollectible amounts (643) (568) Net financed sales receivables 110,054 106,286 Total financing receivables $ 118,897 $ 117,231 Net financed sales receivables due within one year $ 21,260 $ 19,068 Net financed sales receivables due after one year $ 88,794 $ 87,218 As at September 30, 2016 , the financed sale receivables had a weighted average effective interest rate of 9.2 % (December 31, 2015 — 9.4 %).

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventories [Abstract]
Inventories	4. Inventories September 30, December 31, 2016 2015 Raw materials $ 32,662 $ 25,750 Work-in-process 4,215 2,628 Finished goods 14,138 10,375 $ 51,015 $ 38,753 At September 30, 2016 , finished goods inventory for which title had passed to the customer and revenue was deferred amounted to $ 5.1 million (December 31, 2015 — $ 5.4 million). During the three and nine months ended September 30, 2016 , the Company had write-downs for excess and obsolete inventory based upon current estimates of net realizable value co nsidering future events and conditions of a recovery of less than $ 0.1 million and an expense of $ 0.2 million , respectively ( 2015 — recovery of $ 0.1 million and expense of $ 0.4 million, respectively ).

Property Plant and Equipment

Property Plant and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	5. Property Plant and Equipment As at September 30, 2016 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 216,670 $ 86,219 $ 130,451 Camera equipment 5,902 3,750 2,152 222,572 89,969 132,603 Assets under construction 14,890 - 14,890 Other property, plant and equipment Land 8,203 - 8,203 Buildings 68,974 14,306 54,668 Office and production equipment 40,587 21,237 19,350 Leasehold improvements 7,159 2,889 4,270 124,923 38,432 86,491 $ 362,385 $ 128,401 $ 233,984 As at December 31, 2015 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 199,974 $ 74,568 $ 125,406 Camera equipment 5,393 3,368 2,025 205,367 77,936 127,431 Assets under construction 9,616 - 9,616 Other property, plant and equipment Land 8,203 - 8,203 Buildings 67,150 12,679 54,471 Office and production equipment 34,396 17,035 17,361 Leasehold improvements 3,512 2,327 1,185 113,261 32,041 81,220 $ 328,244 $ 109,977 $ 218,267

Other Intangible Assets

Other Intangible Assets	9 Months Ended
	Sep. 30, 2016
Other Intangible Assets [Abstract]
Other Intangible Assets	6. Other Intangible Assets As at September 30, 2016 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 11,181 $ 6,928 $ 4,253 Licenses and intellectual property 22,490 7,295 15,195 Other 14,023 3,866 10,157 $ 47,694 $ 18,089 $ 29,605 As at December 31, 2015 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 10,399 $ 6,502 $ 3,897 Licenses and intellectual property 22,390 6,464 15,926 Other 11,878 2,751 9,127 $ 44,667 $ 15,717 $ 28,950 Other intangible assets of $ 14.0 million are comprised mainly of the Company’s investment in an enterprise resource planning system. Fully amortized other intangible assets are still i n use by the Company. During the nine months ended September 30, 2016 , the Company acquired $ 3.2 million in other intangible assets. The weighted average amortization period for these additions was 10 years. During the three and nine months ended September 30, 2016 , the Company incurred costs of less than $ 0.1 million and $ 0.2 million , respectively, to renew or extend the term of acquired other intangible assets which were recorded in selling, general and administrative expenses ( 2015 – less than $0.1 million and less than $0.1 million, resp ectively). As at September 30, 2016 , estimated amortization expense for each of the years ended December 31, are as follows: 2016 (three months remaining) $ 858 2017 3,270 2018 3,270 2019 3,270 2020 3,270

Credit Facility and Playa Vista

Credit Facility and Playa Vista Loan	9 Months Ended
	Sep. 30, 2016
Credit Facility and Playa Vista Construction Loan [Abstract]
Credit Facility and Playa Vista Construction Loan [Text Block]	7. Credit Facility and Playa Vista Loan On March 3, 2015, the Company amended and restated the terms of its existing senior secured credit facility (the “Prior Credit Facility”) in order to, among other things, eliminate the fixed charge coverage ratio under the Prior Credit Facility and reset certain financial maintenance covenants. The amended and restated facility (the “Credit Facility”), with a scheduled maturity of March 3, 2020, has a maximum borrowing capacity of $ 200.0 million, the same maximum borrowing capacity as under the Prior Credit Facility. Certain of the Company’s subsidiaries serve as guarantors (the “Guarantors”) of the Company’s obl igations under the Credit Facility. The Credit Facility is collateralized by a first priority security interest in substantially all of the present and future assets of the Company and the Guarantors. The terms of the Credit Facility are set forth in the Fourth Amended and Restated Credit Agreement (as amended, the “Credit Agreement”), dated March 3, 2015, among the Company, the Guarantors, the lenders named therein, Wells Fargo Bank, National Association (“Wells Fargo”), as agent and issuing lender (Well s Fargo, together with the lenders named therein, the “Lenders”) and Wells Fargo Securities, LLC, as Sole Lead Arranger and Sole Bookrunner and in various collateral and security documents entered into by the Company and the Guarantors. Each of the Guarant ors has also entered into a guarantee in respect of the Company’s obligations under the Credit Facility. On February 22, 2016, the Company amended the terms of the Credit Agreement to increase the general restricted payment basket thereunder (which covers, among other things, the repurchase of shares) from $150.0 million to $350.0 million in the aggregate after the amendment date. The Company was in compliance with all of its requirements at September 30, 2016 . Total amounts drawn and available under the Credit Facility at September 30, 2016 were $nil and $ 200.0 million, respectively (December 31, 2015 — $nil and $ 200.0 million, respectively). As at September 30, 2016 , the Company did not have any letters of credit and advance payment guarantees outstanding (December 31, 2015 — $nil), under the Credit Facility. Playa Vista Financing On October 6, 2014, IMAX PV Development Inc., a Delaware corporation (“PV Borrower”) and wholly-owned subsidiary of the Company, en tered into a construction loan agreement with Wells Fargo. The construction loan (the “Playa Vista Construction Loan”) was used to fund $22.3 million of the costs of development and construction of the West Coast headquarters of the Company, located in the Playa Vista neighborhood of Los Angeles, California (the “Playa Vista Project”). The total cost of development of the Playa Vista Project was approximately $54.0 million, with all costs in excess of the Playa Vista Construction Loan provided through fun ding by the Company. The Company began occupying the Playa Vista facility in March of 2015. On October 19, 2015, PV Borrower converted the Playa Vista Construction Loan from a construction loan into a permanent loan (“Playa Vista Loan”) pursuant to the t erms of the loan documents. Pursuant to the conversion, PV Borrower increased the principal balance of the loan by an additional $7.7 million, to $30.0 million. Prior to the conversion, the Playa Vista Construction Loan bore interest at a variable interest rate per annum equal to 2.25% above the 30-day LIBOR rate, and PV Borrower was required to make monthly payments of interest only. However, as a result of the conversion, the interest rate decreased from 2.25% to 2.0% above the 30-day LIBOR rate, and PV B orrower will be required to make monthly payments of combined principal and interest over a 10-year term with a lump sum payment at the end of year 10. The Playa Vista Loan is being amortized over 15 years. The Playa Vista Loan will be fully due and payabl e on October 19, 2025 (the “Maturity Date”), and may be prepaid at any time without premium, but with all accrued interest and other applicable payments. The Playa Vista Loan is secured by a deed of trust from PV Borrower in favor of Wells Fargo, granting a first lien on and security interest in the Playa Vista property and the Playa Vista Project, including all improvements to be constructed thereon, and other documents evidencing and securing the loan (the “Loan Documents”). The Loan Documents include ab solute and unconditional payment and completion guarantees provided by the Company to Wells Fargo for the performance by PV Borrower of all the terms and provisions of the Playa Vista Loan and an environmental indemnity also provided by the Company. The L oan Documents contain affirmative, negative and financial covenants (including compliance with the financial covenants of the Company’s outstanding revolving senior secured facility with Wells Fargo), agreements, representations, warranties, borrowing cond itions, and events of default customary for development projects such as the Playa Vista Project. Bank indebtedness includes the following: September 30, December 31, 2016 2015 Playa Vista Loan $ 28,167 $ 29,667 Deferred charges on debt financing (361) (391) $ 27,806 $ 29,276 Total amounts drawn under the loan at September 30, 2016 was $ 28.2 million (December 31, 2015 — $ 29.7 million) . The effective interest rate for the three and nine months ended September 30, 2016 was 2.51 % and 2.46 %, respectively ( 2015 — 2.45 % and 2.44 %, respectively ). In accordance with the loan agreement, the Company is obligated to make payments on the principal of the loan as follows: 2016 (three months remaining) $ 500 2017 2,000 2018 2,000 2019 2,000 2020 2,000 Thereafter 19,667 $ 28,167 Wells Fargo Foreign Exchange Facility Within the Credit Facility, the Company is able to purchase foreign currency forward contracts and/or other swap arrangements. The re is no settlement risk on its foreign currency forward contracts at September 30, 2016 as the fair val ue exceeded t he notional value of the forward contracts. As at September 30, 2016 , the Company has $ 26.9 million in notional value of such arrangements outstandin g. Bank of Montreal Facility As at September 30, 2016 , the Company has available a $ 10.0 million facility (December 31, 2015 — $ 10.0 million) with the Bank of Montreal for use solely in conjunction with the issuance of performance guarantees and letters of credit fully insured by Export Development Canada (the “Bank of Montreal Facili ty”). As at September 30, 2016 , the Company has letters of credit and advance payment guarantees outstanding of $ 0.1 million (December 31, 2015 — $ 0.3 million) under the Bank of Montreal Facility.

Contingencies and Guarantees

Contingencies and Guarantees	9 Months Ended
	Sep. 30, 2016
Commitments, Contingencies and Guarantees [Abstract]
Contingencies and Guarantees	8. Contingencies and Guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. In accordance with the Contingencies Topic of the FASB ASC, the Company will make a provision for a liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company believes it has adequate provisions for any su ch matters. The Company reviews these provisions in conjunction with any related provisions on assets related to the claims at least quarterly and adjusts these provisions to reflect the impacts of negotiations, settlements, rulings, advice of legal counse l and other pertinent information related to the case. Should developments in any of these matters outlined below cause a change in the Company’s determination as to an unfavorable outcome and result in the need to recognize a material provision, or, shoul d any of these matters result in a final adverse judgment or be settled for significant amounts, they could have a material adverse effect on the Company’s results of operations, cash flows, and financial position in the period or periods in which such a c hange in determination, settlement or judgment occurs. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred. On May 15, 2006, the Company initiated arbitration against Three-Dimensional Media Group, Ltd. (“3DMG”) before the International Centre for Dispute Resolution in New York (the “ICDR”), alleging breaches of the license and consulting agreements between the Company and 3DMG. On June 15, 2006, 3DMG filed an answer denying any breaches and asserting counterclaim s that the Company breached the parties’ license agreement. On June 21, 2007, the ICDR unanimously denied 3DMG’s Motion for Summary Judgment filed on April 11, 2007 concerning the Company’s claims and 3DMG’s counterclaims. The proceeding was suspended on M ay 4, 2009 due to failure of 3DMG to pay fees associated with the proceeding. The proceeding was further suspended on October 11, 2010 pending resolution of re-examination proceedings involving one of 3DMG’s patents. Following a status conference on April 27, 2016 before the ICDR, the ICDR granted 3DMG leave to amend its answer and counterclaims, and subsequently lifted the stay in this matter. In its amended counterclaims, 3DMG seeks damages for alleged unpaid royalties and other fees under the license and consulting agreements. Discovery is currently ongoing and a final hearing before the ICDR has been scheduled for the week of July 10, 2017. Given the stage of discovery, the Company is unable to determine a range of potential damages in this matter. Howev er, t he Company believes that the amount of loss, if any, suffered in connection with the amended counterclaims would not have a material impact on the financial position or results of operations of the Company, although no assurance can be given with res pect to the ultimate outcome of the arbitration. In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) with respect to the breach by Electronic Media Limited (“EML”) of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML’s affiliate, E-City Entertainment ( I) PVT Limited (“E-City”). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,5 12 each day in interest from October 1, 2007 until the date the award is paid. In July 2008, E-City commenced a proceeding in Mumbai, India seeking an order that the ICC award may not be recognized in India. The Company has opposed that application on a nu mber of grounds and seeks to have the ICC award recognized in India. On June 13, 2013, the Bombay High Court ruled that it has jurisdiction over the proceeding but on November 19, 2013, the Supreme Court of India stayed proceedings in the High Court pendin g Supreme Court review of the High Court’s ruling. On June 24, 2011, the Company commenced a proceeding in the Ontario Superior Court of Justice for recognition of the ICC final award. On December 2, 2011, the Ontario Court issued an order recognizing the final award and requiring E-City to pay the Company $30,000 to cover the costs of the application. In January 2013, the Company filed an action in the New York Supreme Court seeking to collect the amount owed to the Company by certain entities and individu als affiliated with E-City. On October 16, 2015, the New York Supreme Court denied the Company’s petition, and the Company is appealing that decision. On July 29, 2014, the Company commenced a separate proceeding to have the Canadian judgment against E-Cit y recognized in New York, and on October 2, 2015, the New York Supreme Court granted IMAX’s request, recognizing the Canadian judgment and entering it as a New York judgment. On November 26, 2014, E-City filed a motion in the Bombay High Court seeking to e njoin IMAX from continuing the New York legal proceedings. On February 2, 2015, the Bombay High Court denied E-City’s request for an injunction. On March 16, 2015, E-City filed an appeal of this Bombay High Court decision. In March 2013, IMAX (Shanghai) M ultimedia Technology Co., Ltd., the Company’s majority-owned subsidiary in China, received notice from the Shanghai office of the General Administration of Customs that it had been selected for a customs audit. In the third quarter of 2016, IMAX (Shanghai) Multimedia Technology Co., Ltd put forth a proposal to the Shanghai office of the General Administration of Customs in an attempt to resolve the audit issue of what costs should be subject to duties and taxes on importation into China. As a result of the p roposal, the Company has accrued $1.6 million as at September 30, 2016, of which $0.8 million is recorded in costs and expenses applicable to revenues and $0.8 million is recorded in property, plant and equipment. An additional $1.8 million will be paid to the authorities as value-added tax, which local management believes i s collectible in the form of future input tax credits, and therefore has been presented as a net balance of $nil in Accrued and other liabilities as at September 30, 2016. The Company is unable to assess any other potential impact of the customs audit, if any, at this time . On November 11, 2013, Giencourt Investments, S.A. (“Giencourt”) initiated arbitration before the International Centre for Dispute Resolution in Miami, Florida, based on alleged breaches by the Company of its theater agreement and related license agreement with Giencourt. Giencourt submitted its statement of claim in January 2015, the Company submitted its statement of defense and counterclaim in April 2015 and Giencour t submitted its arbitration reply paper in September 2015. An arbitration hearing for witness testimony was held during the week of December 14, 2015. At the hearing, Giencourt’s expert identified monetary damages of up to approximately $10.4 million, whic h Giencourt seeks to recover from the Company. The Company has asserted a counterclaim against Giencourt for breach of contract and seeks to recover lost profits in excess of $24.0 million under the agreements. A final hearing with closing statements is sc heduled for October 20 and 21, 2016. In addition, on December 10, 2015, Giencourt made a motion to the panel seeking to enforce a purported settlement of the matter based on negotiations between Giencourt and the Company. The Company strongly disputes that discussions about a potential resolution of this matter amounted to an enforceable settlement. The panel has asked the parties to brief this issue, and oral arguments will be held during the upcoming October hearings. Although no assurances can be given w ith respect to the ultimate outcome of the proceedings, the Company believes that it has meritorious defenses and claims, and will continue to vigorously pursue them . In addition to the matters described above, the Company is currently involved in other l egal proceedings or governmental inquiries which, in the opinion of the Company’s management, will not materially affect the Company’s financial position or future operating results, although no assurance can be given with respect to the ultimate outcome o f any such proceedings. In the normal course of business, the Company enters into agreements that may contain features that meet the definition of a guarantee. The Guarantees Topic of the FASB ASC defines a guarantee to be a contract (including an indemni ty) that contingently requires the Company to make payments (either in cash, financial instruments, other assets, shares of its stock or provision of services) to a third party based on (a) changes in an underlying interest rate, foreign exchange rate, equ ity or commodity instrument, index or other variable, that is related to an asset, a liability or an equity security of the counterparty, (b) failure of another party to perform under an obligating agreement or (c) failure of another third party to pay its indebtedness when due. Financial Guarantees The Company has provided no significant financial guarantees to third parties. Product Warranties The following summarizes the accrual for product warranties that was recorded as part of accrued liabilities in the condensed consolidated balance sheets: September 30, December 31, 2016 2015 Balance at the beginning of period $ - $ 6 Warranty redemptions - (6) Warranties issued 15 - Revisions - - Balance at the end of period $ 15 $ - Director/Officer Indemnifications The Company’s General By-law contains an indemnification of its directors/officers, former directors/officers and persons who have acted at its request to be a director/officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the Canada Business Corporations Act , against expenses (including legal fees), judgments, fines and any amounts actually and reasonably incurred by them in connection with any action, suit or proceeding in which the directors and /or officers are sued as a result of their service, if they acted honestly and in good faith with a view to the best interests of the Company. The nature of the indemnification prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. The Company has purchased directors’ and officers’ liability insurance. No amount has been accrued in the condensed consolidated balance sheet as at September 30, 2016 and December 31, 2015 with respect to this indemnity. Other Indemnification Agreements In the normal course of the Company’s operations, the Company provides indemnifications to counterparties in tra nsactions such as: theater system lease and sale agreements and the supervision of installation or servicing of the theater systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These i ndemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company’s breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnifi cation; however, virtually all of the Company’s system lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specif ied in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnifications and no amoun ts have been accrued in the condensed consolidated financial statements with respect to the contingent aspect of these indemnities.

Condensed Consolidated Statem16

Condensed Consolidated Statements of Operations Supplemental Information	9 Months Ended
	Sep. 30, 2016
Basis of Presentation and Condensed Consolidated Statements of Operations Supplemental Information [Abstract]
Condensed Consolidated Statements of Operations Supplemental Information	9. Condensed Consolidated Statements of Operations Supplemental Information Selling Expenses The Company defers direct selling costs such as sales commissions and other amounts related to its sale and sales-type lease arrangements until the related revenue is recognized. These costs and direct advertising and marketing, included in costs and expenses applicable to revenues-equipment and product sales, totaled $ 1.3 million an d $ 3.0 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 1.3 million and $ 2.8 million, respectively). Film exploitation costs, including advertising and marketing, totaled $ 4.8 million and $ 13.8 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 3.4 million and $ 8.2 million, respecti vely) and are recorded in costs and expenses applicable to revenues-services as incurred. Commissions are recognized as costs and expenses applicable to revenues-rentals in the month they are earned. These costs totaled $ 0.6 m illion and $ 0.9 million for the three and nine months ended September 30, 2016 , respectively ( 2015 —$ 0.3 million and $ 0.5 million, respectively). Direct advertising and marketing costs for each theater are charged to costs and expenses applicable to revenues-rentals as incurred. These costs totaled an expense of $ 0.4 million and $ 1.0 million for the three and nine months ended September 30, 2016 , respectively ( 2015 —$ 0.6 million and $ 1.2 million, respectively). Foreign Exchange Included in selling, general and administrative expenses for the three and nine months ended September 30, 2016 is a loss of $ 0.2 mil lion and a loss of $ 0.1 million, respectively ( 2015 — loss of $ 0.5 million and a loss of $ 1.5 million, respectively), for net foreign exchange gai ns/losses related to the translation of foreign currency denominated monetary assets and liabilities. See note 15(d) for additional information. Collaborative Arrangements Joint Revenue Sharing Arrangements In a joint revenue sharing arrangement, the Co mpany receives a portion of a theater’s box-office and concession revenues, and in some cases a small upfront or initial payment, in exchange for placing a theater system at the theater operator’s venue. Under joint revenue sharing arrangements, the custom er has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to equipment under joint revenue sharing arrangements generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the term. The customer is requi red to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the theater systems commencing on the date specified in the arrangement’s shipping terms and ending on the date the theater systems are delivered back to the Company. The Company has signed joint revenue sharing agreements with 49 exhibitors for a total of 981 theater systems, of which 592 theaters were operating as at September 30, 2016 , the terms of which are similar in nature, rights and obligations. The acco unting policy for the Company’s joint revenue sharing arrangements is disclosed in note 2(m) of the Company’s 2015 Form 10-K. Amounts attributable to transactions arising between the Company and its customers under joint revenue sha ring arrangements are included in Equipment and Product Sales and Rentals revenue and for the three and nine months ended September 30, 2016 amounted to $ 19.7 million and $ 66.9 million, respectively ( 2015 — $ 19.8 million and $ 67.3 million, respectively). IMAX DMR In an IMAX DMR arrangement, the Company transforms conventional motion pictures into the Company’s large screen format, allowing the release of Hollywood content to the global IMAX theater network. In a typical IMAX DMR film arrangement, the Company will a bsorb its costs for the digital re-mastering and then recoup this cost from a percentage of the net box-office receipts of the film, which in recent years has ranged from 10-15%. The Company does not typically hold distribution rights or the copyright to t hese films. For the nine months ended September 30, 2016 , the majority of IMAX DMR revenue was earned from the exhibition of 48 IMAX DMR films ( 2015 – 48 ) throughout the IMAX theater network. The accounting policy for the Company’s IMAX DMR arrangements is disclosed in note 2(m) of the Company’s 2015 Form 10-K. Amounts attributable to transactions arising between the Compan y and its customers under IMAX DMR arrangements are included in Services revenue and for the three and nine months ended September 30, 2016 amounted to $ 21.6 million and $ 78.8 million, respectively ( 2015 — $ 20.9 million and $ 75.1 million, respectively). Co-Produced Film Arrangements In certain film arrangements, the Company co- produces a film with a third party whereby the third party retains the copyright and rights to the film and the Company obtains exclusive theatrical distribution rights to the film. Under these arrangements, both parties contribute funding to the Company’s wholly-owned production company for the production of the film and for associated exploitation costs. Clauses in the film arrangements generally provide for the third party to take over the production of the film if the cost of the production exceeds its approved budget or if it appears as though the film will not be delivered on a timely basis. The accounting policies relating to co-produced film arrangements are disclosed in notes 2(a) and 2(m) of the Company’s 2015 Form 10-K. As at September 30, 2016 , the Company has one significant co-produced film arrangement which represents the VIE total assets balance of $ 0.4 million and total liabi lities balance of $ 0.4 million and five other co-produced film arrangements, the terms of which are similar. For the three and nine months ended September 30, 2016 , amounts totaling $ 0.5 million and $ 1.0 million, respectively ( 2015 — $ 0.3 million and $ 1.4 million, respectively) attributa ble to transactions between the Company and other parties involved in the production of the films have been included in cost and expenses applicable to revenues-services.

Condensed Consolidated Statem17

Condensed Consolidated Statements of Cash Flows Supplemental Information	9 Months Ended
	Sep. 30, 2016
Condensed Consolidated Statements of Cash Flows Supplemental Information [Abstract]
Condensed Consolidated Statements of Cash Flows Supplemental Information	10. Condensed Consolidated Statements of Cash Flows Supplemental Information Changes in other non-cash operating assets and liabilities are comprised of the following: Nine Months Ended September 30, 2016 2015 Decrease (increase) in: Accounts receivable $ 6,571 $ (12,048) Financing receivables (1,145) (9,932) Inventories (12,508) (18,904) Prepaid expenses (5,105) (2,159) Commissions and other deferred selling expenses 285 (206) Insurance recoveries 132 28 Other assets (1,299) (2,388) Increase (decrease) in: Accounts payable (6,616) 4,212 Accrued and other liabilities (1,991) (17,528) Deferred revenue (7,828) 17,892 $ (29,504) $ (41,033) Cash payments made on account of: Nine Months Ended September 30, 2016 2015 Income taxes $ 20,822 $ 21,542 Interest $ 541 $ 302 Depreciation and amortization are comprised of the following: Nine Months Ended September 30, 2016 2015 Film assets $ 11,842 $ 11,917 Property, plant and equipment Joint revenue sharing arrangements 11,581 10,043 Other property, plant and equipment 7,355 5,635 Other intangible assets 2,368 2,354 Other assets 631 579 Deferred financing costs 402 663 $ 34,179 $ 31,191 Write-downs, net of recoveries, are comprised of the following: Nine Months Ended September 30, 2016 2015 Accounts receivable $ 556 $ 709 Financing receivables 75 - Inventories 246 405 Film assets 1,000 - Property, plant and equipment 792 1,464 Impairment of investments 194 350 Other intangible assets 40 - $ 2,903 $ 2,928

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Taxes [Abstract]
Income Taxes	11. Income Taxes Income Taxes The Company’s effective tax rate differs from the statutory tax rate and varies from year to year primarily as a result of permanent differences, investment and other tax credits, the provision for income taxes at different rates in foreign and other provincial jurisdictions, enacted statutory tax rate increases or reductions in the year, changes due to foreign exchange, changes in the Company’s valuation allowance based on the Comp any’s recoverability assessments of deferred tax assets, and favorable or unfavorable resolution of various tax examinations. During the quarter ended September 30, 2016 , there was no change in the Company’s estimates of the recoverability of its deferred tax assets based on an analysis of both positive and negative evidence including projected future earnings. As at September 30, 2016 , the Company had net deferred income tax assets after valuation allowance of $ 26.2 million (December 31, 2015 — $ 26.7 million), which consists of a gross deferred inco me tax asset of $ 26.5 million (December 31, 2015 — $ 27.0 million), against which the Company is carrying a $ 0.3 million valuation allowance (Decem ber 31, 2015 — $ 0.3 million). ASU 2016-09 , related to stock-based compensation, was issued in March 2016 and early adopted by the Company in June 2016. ASU 2016-09 eliminates additional paid in capital ( "APIC") pools and requires excess tax benefits and tax deficiencies to be recorded in the condensed consolidated statement s of operations when the awards vest or are settled. Amendments related to accounting for excess tax benefits have been adopted prospe ctively resulting in a tax benefit of $nil and $0.1 million for the three and nine months ended September 30, 2016, respectively. In addition, modified retrospective adoption of ASC 2016-09 eliminates the requirement that excess tax benefits be realized be fore they can be recognized. The Company has also recorded a cumulative-effect adjustment of $0.9 million to Accumulated earnings and Deferred income taxes related to the impact from adoption of the provisions related to forfeiture rates. See Notes 2 and 1 2 for further discussion of the impact from the adoption of ASU 2016-09. Income Tax Effect on Other Comprehensive (Loss) Income The income tax (expense) benefit included in the Company’s other comprehensive (loss) income are related to the following item s: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Unrealized change in cash flow hedging instruments $ 76 $ 606 $ (485) $ 1,309 Realized change in cash flow hedging instruments upon settlement (149) (274) (667) (577) Amortization of actuarial loss on postretirement benefit plan (4) - (14) - Foreign currency translation adjustments - 226 - 264 $ (77) $ 558 $ (1,166) $ 996

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2016
Capital Stock [Abstract]
Capital Stock	12. Capital Stock Stock-Based Compensation The compensation costs recorded in the condensed consolidated statements of operations for the Company’s stock-based compensation plans were $ 7.7 million and $ 22.5 million for the three and nine months ended September 30, 2016 , respectively ( 2015 —$ 4.3 million and $ 14.9 million, respectively). As at September 30, 2016 , the Company has reserved a total of 12,467,960 (December 31 , 2015 — 7,023,258 ) common shares for future issuance under the Company’s Stock Option Plan (“SOP”) and the IMAX Corporation Amended and Restated Long-Term Incentive Plan (“IMAX LTIP”). Of the common shares reserved for issuance, there are options in respect of 5,473,673 common shares and restricted share units (“RSUs”) in respect of 1,140,138 common sha res outstanding at September 30, 2016 . At September 30, 2016 , options in respect of 3,924,432 common shares were vested and exercisable. Stock Option Plan The Company recorded an expense of $ 3.4 million and $ 9.4 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 2.3 million and $ 8.4 million, respectively) related to stock option grants issued to employees and direc tors in the IMAX LTIP and SOP plans. An income tax benefit is recorded in the condensed consolidated statements of operations of $ 0.9 million and $ 2.4 million for the three and nine months ended September 30, 2016 , respectively ( 2015 —$ 0.5 million and $ 1.8 million, respectively), for these costs. The weighted average fair val ue of all stock options granted to employees and directors for the three and nine months ended September 30, 2016 at the grant date was $ 7.80 and $ 8.16 per share, respectively ( 2015 — n/a and $ 8.07 per share, respectively). The following assumptions were used to estimate the average fair value of t he stock options: Three Months Nine Months Ended September 30, Ended September 30, 2016 2015 2016 2015 Average risk-free interest rate 1.44% n/a 1.67% 1.97% Expected option life (in years) 4.44 - 4.88 n/a 4.44 - 5.24 3.55 - 5.76 Expected volatility 30% n/a 30% 30% Dividend yield 0% n/a 0% 0% Stock options to Non-Employees There were no common share options issued to non-employees during the three and nine months ended September 30, 2016 and 2015 . As at September 30, 2016 , non-employee stock options outstanding amounted to 28,750 stock options ( 2015 — 39,500 ) with a weighted average exercise price of $ 26.90 per share ( 2015 — $ 26.78 per share ). 26,950 stock options ( 2015 — 21,525 ) were exercisable with an average weighted exercise price of $ 26.97 per share ( 2015 — $ 26.34 per share ) and the vested stock options have an aggregate intrinsic value of $ 0.1 million ( 2015 — $ 0.2 million). For the three and nine months ended September 30, 2016 , the Company recorded an expense of less than $0.1 million and a recovery less than $0.1 million, respectively ( 2015 — expense of less than $0.1 million and $ 0.1 million, respectively) to cost and expenses re lated to revenues – services and selling, general and administrative expenses related to the non-employee stock options. Included in accrued liabilities is an accrual of less than $0.1 million for non-employee stoc k options (December 31, 2015 — less than $0.1 million). China Long Term Incentive Plan (“China LTIP”) The China LTIP was adopted by IMAX China Holding, Inc. (“IMAX China”), a subsidiary of the Company, in October 2012. Each stock option (“China Option”), RSU or cash settled share-based payment (“CSSBP”) issued under the China LTIP represents an opportunity to participate economically in the future growth and value creation of IMAX China. Prior to the in itial public offering of IMAX China on October 8, 2015 (the “IMAX China IPO”), the China Options and CSSBPs issued by IMAX China operated in tandem with options granted to certain employees of IMAX China under the Company’s SOP and the IMAX LTIP (“Tandem O ptions”). During 2015, no Tandem Options were granted in conjunction with China Options or CSSBPs. Immediately prior to the IMAX China IPO, there were 186,446 outstanding and unvested Tandem Options issued under the Company’s SOP and IMAX LTIP with a weig hted average exercise price of $23.70 per share. The Tandem Options had a maximum contractual life of 7 years. The total fair value of the Tandem Options granted with respect to the China LTIP was $1.9 million. The Company was recognizing this expense over a 5 year period. Pursuant to their terms, upon the occurrence of a qualified initial public offering or upon a change in control on or prior to the fifth anniversary of the grant date, the 186,446 Tandem Options issued would forfeit immediately and the related charge would be reversed. As a result of the IMAX China IPO on October 8, 2015, the 186,446 Tandem Options with an average price of $23.70 per share were forfeited immediately. The Company recorded a recovery of $0.6 million in 2015 related to the forfeiture of Tandem Options issued under the Company’s SOP and IMAX LTIP. During the three and nine months ended September 30, 2015, the Company recorded an expense of $0.1 million and $0.3 million, respectively, related to the Tandem Options. The Company subsequently recognized an immediate charge related to the vesting of China Options and certain CSSBPs for China employees. The total fair value of the China Options and CSSBP awards granted with respect to the C hina LTIP was $3.9 million and $2.1 million, respectively. During the fourth quarter of 2015, a charge of $2.1 million and $1.4 million was recorded relating to the China Options and CSSBPs, respectively. The remaining charge will be recognized over the re lated requisite period. The CSSBPs represent the right to receive cash payments in an amount equal to a certain percentage of the excess of the total equity value of IMAX China based on the per share price in the IMAX China IPO over the strike price of the CSSBPs. The CSSBPs were issued in conjunction with the China LTIP, with similar terms and conditions as the China Options. The CSSBP awards are accounted as liability awards, however the fair value of the liability is fixed at the time of the initial publ ic offering. During the fourth quarter of 2015, a portion of the CSSBPs vested and were settled in cash for $1.0 million. In connection with the IMAX China IPO and in accordance with the China LTIP, IMAX China adopted a post-IPO share option plan and a post-IPO restricted stock unit plan. Pursuant to these plans, IMAX China issued additional China Options and China LTIP Restricted Share Units (“China RSUs”) during the nine months ended September 30, 2016 . No addi tional China Options and China RSUs were issued for the three months ended September 30, 2016 . During the three and nine months ended September 30, 2016 , the Company recorded an expense related to the China Options, China RSUs and CSSBPs of $0.2 million and $0.7 million, $0.1 million and $0.4 million and $0.1 million and $0.3 million, respectively. The liability recognized with respect to the CSSBPs a s at September 30, 2016 was $0.7 million (December 31, 2015 — $0.4 million). Stock Option Summary The following table summarizes certain information in respect of option activity under the SOP and IMAX LTIP for the nine month periods ended September 30 : Weighted Average Exercise Number of Shares Price Per Share 2016 2015 2016 2015 Options outstanding, beginning of period 4,805,244 5,925,660 $ 27.03 $ 24.24 Granted 984,452 871,431 31.49 31.56 Exercised (268,516) (1,231,964) 20.54 19.35 Forfeited (45,024) (45,474) 28.03 28.26 Cancelled (2,483) - 33.80 - Options outstanding, end of period 5,473,673 5,519,653 28.14 26.45 Options exercisable, end of period 3,924,432 3,195,836 27.34 25.14 The Company cancelled 2,483 stock options from its IMAX LTIP surrendered by a Company employee during the three and nine months ended September 30, 2016 , respectively ( 2015 – nil and nil, respectively). No stock options were cancelled from its SOP surrendered by Company employees during the three and nine months ended September 30, 2016 and 2015 . As at September 30, 2016 , options that are exercisable have an intrinsic value of $ 9.7 million and a weighted average remaining contractual life of 3.9 years. The intrinsic value of options exercised in the three and nine months ended September 30, 2016 was $ 0.5 million and $ 3.2 million, respectively ( 2015 — $ 1.2 million and $ 21.4 million, respectively). Restricted Share Units RSUs have been granted to employees, consultants and directo rs under the IMAX LTIP. Each RSU represents a contingent right to receive one common share and is the economic equivalent of one common share. The grant date fair value of each RSU is equal to the share price of the Company’s stock at the grant date. The C ompany recorded an expense of $ 3.9 million and $ 11.6 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 1.9 million and $ 6.2 million, respectively), related to RSU grants issued to employees and directors in the plan. In addition, the Company recorded an expense of $nil and $nil for the three an d nine months ended September 30, 2016 , respectively ( 2015 — less than $0.1 million and less than $0.1 mill ion, respectively), related to RSU grants issued to certain advisors and strategic partners of the Company. During the three and nine months ended September 30, 2016 , in connection with the vesting of RSUs, the Co mpany settled 27,416 and 271,032 , respectively ( 2015 — 32,345 and 192,077 , respectively) common shares to IMAX LTIP participa nts, of which 21,871 and 50,167 , respectively ( 2015 — nil and 21,709 , respectively) common shares, net of shares withheld for tax withholdings of 5,328 and 8,836 , respectively (2015 — 5,763 and 5,981 , respectively) were issued from treasury and 217 and 212,029 , respectively ( 2015 — 26,582 and 164,387 , respectively) common shares were settled through the open market purchases by the IMAX LTIP trus tee. Total stock-based compensation expense related to non-vested RSUs not yet recognized at September 30, 2016 and the weighted average period over which the awards are expected to be recog nized is $ 26.8 million and 2.4 years, respectively ( 2015 — $ 16.4 million and 3.0 years, respectively). The Company’s actual tax benefits realized for the tax deductions related to the vesting of RSUs was $ 0.3 million and $ 2.6 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 0.4 million and $ 2.0 million, respectively). Historically, RSUs granted under t he IMAX LTIP have vested between immediately and four years from the grant date. In connection with the amendment and restatement of the IMAX LTIP at the Company’s annual and special meeting of shareholders on June 6, 2016, the IMAX LTIP plan was amended t o impose a minimum one-year vesting period on future RSU grants, with a carve-out for 300,000 RSUs that may vest on a shorter schedule. Vesting of the RSUs is subject to continued employment or service with the Company. The following table summarizes cert ain information in respect of RSU activity under the IMAX LTIP for the nine months ended September 30 : Number of Awards Weighted Average Grant Date Fair Value Per Share 2016 2015 2016 2015 RSUs outstanding, beginning of period 973,637 595,834 $ 32.27 $ 27.13 Granted 465,968 337,557 31.70 34.39 Vested and settled (271,032) (192,077) 29.30 28.93 Forfeited (28,435) (19,499) 30.78 29.37 RSUs outstanding, end of period 1,140,138 721,815 32.78 29.99 As at September 30, 2016 , the IMAX LTIP trustee held 176 shares purchased for less than $0.1 million in the open market to be issued upon the s ettlement of RSUs. The shares held with the trustee are recorded at cost and are reported as a reduction against capital stock on the condensed consolidated balance sheet. Issuer Purchases of Equity Securities On June 16, 2014 , the Company’s board of directors approved a new $150.0 million share repurchase program for shares of the Company’s common stock, which program was amended on April 20, 2016 to increase the aggregate purchase allowance to $200.0 million. Purchases under the program commenced during the third quarter of 2014, and the program expires on June 30, 2017. The repurchases may be made either in the open market or through private transactions, subject to market conditions, applicable legal requirements and other r elevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. During the three and nine months ended September 30, 2016 , the Company repurchased 500,000 and 3,290,512 common shares, respectively ( 2015 — 1,000,000 and 1,000,000 common shares, respectively), at an average price of $ 29.32 and $ 30.48 per share, respectively ( 2015 — $34.25 and $34.25 per share, respectively). The retired shares were purchased for $ 14.7 million and $ 100.4 million, respectively ( 2015 — $34.3 million and $34.3 million, respectively). The average carrying value of the stock retired was deducted from common stock and the remaini ng excess over the average carrying value of stock was charged to accumulated deficit. The total number of shares purchased during the three and nine months ended September 30, 2016 does not include any shares pu rchased in the administration of employee share-based compensation plans (which amounted to nil and 249,657 common shares, respectively, at an average price of $nil and $33.55 per share, respectively). Canadian Securities Law Matters The Company has rec eived an exemption decision issued by the Ontario Securities Commission, dated April 1, 2016, for relief from the formal issuer bid requirements under Canadian securities laws. The exemption decision permits the Company to repurchase up to 10% of its outst anding common shares in any twelve-month period through the facilities of the New York Stock Exchange (“NYSE”) under repurchase programs that the Company may implement from time to time. The Canadian securities laws regulate an issuer’s ability to make rep urchases of its own securities. The Company sought the exemption so that it can make repurchases under its repurchase programs in excess of the maximum allowable in reliance on the existing “other published markets” exemption from the formal issuer bid r equirements available under Canadian securities laws. The “other published markets” exemption caps the Company’s ability to repurchase its securities through the facilities of the NYSE at 5% of the issuer’s outstanding securities during any 12-month period . The conditions of the exemption decision are as follows: (i) any repurchases made in reliance on the exemption decision must be permitted under, and part of repurchase programs established and conducted in accordance with, U.S. securities laws and NYSE rules, (ii) the aggregate number of common shares acquired in reliance on the exemption decision by the Company and any person or company acting jointly or in concert with the Company within any 12 months does not exceed 10% of the outstanding common shar es at the beginning of the 12-month period, (iii) the common shares are not listed and posted for trading on an exchange in Canada, (iv) the exemption decision applies only to the acquisition of common shares by the Company within 36 months of the date of the decision, and (v) prior to purchasing common shares in reliance on the exemption decision, the Company discloses the terms of the exemption decision and the conditions applicable thereto in a press release that is issued on SEDAR and includes such lang uage as part of the news release required to be issued in accordance with the “other published markets exemption” in respect of any repurchase program that may be implemented by the Company. Impact of Stock-based Compensation Accounting Standard Update ASU 2016-09, related to stock-based compensation, was issued in March 2016 and early adopted in June 2016. ASU 2016-09 eliminates the requirement to estimate and apply a forfeiture rate to reduce stock compensation expense during the vesting period and, in stead, account for forfeitures as they occur. ASU 2016-09 requires that this change be adopted using the modified retrospective approach. The impact from the adoption of the provisions related to forfeiture rates was reflected on a modified retrospective b asis resulting in a balance sheet reclass of $4.4 million decrease to Accumulated earnings, $0.9 million increase to Deferred income taxes and $5.3 million increase to Other equity. An increase in APIC and a reduction in stock-based compensation expense of $2.7 million for the nine month period ended September 30, 2016 was also recorded. Additionally, ASU 2016-09 addresses the presentation of excess tax benefits and employee taxes paid on the condensed consolidated statement of cash flows. The Company is r equired to present excess tax benefits as an operating activity on the condensed consolidated statement of cash flows, which is where the Company previously classified these items. ASU 2016-09 also requires the presentation of employee taxes as a financing activity on the condensed consolidated statement of cash flows. This change was reflected in the condensed consolidated statement of cash flows retrospectively. See Notes 2 and 11 for further discussion of the impact from the adoption of ASU 2016-09. Inc ome Per Share Reconciliations of the numerator and denominator of the basic and diluted per-share computations are comprised of the following: Three Months Nine Months Ended September 30, Ended September 30, 2016 2015 2016 2015 Net income attributable to common shareholders $ 2,525 $ 8,610 $ 19,843 $ 33,351 Less: Accretion charges associated with redeemable common stock - (263) - (747) Net income applicable to common shareholders $ 2,525 $ 8,347 $ 19,843 $ 32,604 Weighted average number of common shares (000's): Issued and outstanding, beginning of period 67,067 70,152 69,673 68,988 Weighted average number of shares issued (repurchased) during the period 23 (453) (1,620) 594 Weighted average number of shares used in computing basic income per share 67,090 69,699 68,053 69,582 Assumed exercise of stock options and RSUs, net of shares assumed repurchased 656 1,161 668 1,520 Weighted average number of shares used in computing diluted income per share 67,746 70,860 68,721 71,102 The calculation of diluted earnings per share excludes 2,570,983 and 2,834,896 shares, respectively that are issuable upon the vesting of 19,530 and 283,443 RSUs, respectively and the exercise of 2,551,453 and 2,551,453 stock options, respectively for the three and nine months ended September 30, 2016 , as the impact would be antidilutive. The calculation of diluted earnings per share excludes 1,473,950 and 1,067,859 shares, respectively that are issuable upon the vesting of nil and 61,534 RSUs, respectively and the exercise of 1,473,950 and 1,006,325 stock options, respectively for the three and nine months ended September 30, 2015 , as the impact would be antidilutive. As part of the adoption of ASU 2016-09, the excess tax benefit is no longer included in the calculation of diluted shares under the treasury stock method. This has been applied prospectively. Shareholder’s Equity Attributable to Common Shareholders The following summarizes the movement of Shareholders’ Equity attributable to common shareholde rs for the nine months ended September 30, 2016 : Balance as at December 31, 2015 $ 624,791 Net income attributable to common shareholders 19,843 Adjustments to capital stock: Cash received from the issuance of common shares 5,514 Issuance of common shares for vested RSUs 1,121 Fair value of stock options exercised at the grant date 2,104 Average carrying value of repurchased and retired common shares (21,220) Share held in treasury (6) Adjustments to other equity: Employee stock options granted 10,092 Non-employee stock options granted and vested 30 Fair value of stock options exercised at the grant date (2,104) RSUs granted 12,242 RSUs vested (8,793) Stock exercised from treasury shares (1,216) Cash received from the issuance of common shares in excess of par value 1,682 Adjustments to accumulated deficit: Common shares repurchased and retired (79,158) Adjustments to accumulated other comprehensive loss: Unrealized net gain from cash flow hedging instruments 1,865 Realization of cash flow hedging net loss upon settlement 2,565 Foreign currency translation adjustments (434) Amortization of actuarial loss on postretirement benefit plan 51 Tax effect of movement in other comprehensive income (1,166) Balance as at September 30, 2016 $ 567,803

Segmented Information

Segmented Information	9 Months Ended
	Sep. 30, 2016
Segmented Information [Abstract]
Segmented Information	13. Segmented Information The Company has seven reportable segments identified by category of product sold or service provided: IMAX systems; theater system maintenance; joint revenue sharing arrangements; film production and IMAX DMR; film distribution; film post-production; and other. The IMAX systems segment includes the design, manufacture, sale or lease of IMAX theater projection system equipment. The theater system maintenance segment includes the maintenan ce of IMAX theater projection system equipment in the IMAX theater network. The joint revenue sharing arrangements segment includes the provision of IMAX theater projection system equipment to an exhibitor in exchange for a share of the box-office and conc ession revenues. The film production and IMAX DMR segment includes the production of films and the performance of film re-mastering services. The film distribution segment includes the distribution of films for which the Company has distribution rights. Th e film post-production segment provides film post-production and film print services. The Company refers to all theaters using the IMAX theater system as “IMAX theaters”. The other segment includes certain IMAX theaters that the Company owns and operates, camera rentals and other miscellaneous items. The accounting policies of the segments are the same as those described in note 2 to the audited consolidated financial statements included in the Company’s 2015 Form 10-K. Management, i ncluding the Company’s Chief Executive Officer (“CEO”) who is the Company’s Chief Operating Decision Maker (as defined in the Segment Reporting Topic of the FASB ASC), assesses segment performance based on segment revenues, gross margins and film performan ce. Selling, general and administrative expenses, research and development costs, amortization of intangibles, receivables provisions (recoveries), write-downs net of recoveries, interest income, interest expense and tax (provision) recovery are not alloca ted to the segments. Transactions between the film production and IMAX DMR segment and the film post-production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below. Transacti ons among the other segments are not significant. Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Revenue (1) IMAX theater systems IMAX systems $ 25,687 $ 30,153 $ 70,508 $ 64,632 Theater system maintenance 10,293 9,337 30,031 27,345 Joint revenue sharing arrangements 19,698 19,797 66,940 67,259 55,678 59,287 167,479 159,236 Films Production and IMAX DMR 21,549 20,865 78,767 75,144 Distribution 2,092 967 3,345 3,513 Post-production 2,327 761 6,436 5,259 25,968 22,593 88,548 83,916 Other 4,904 3,221 14,394 11,320 Total $ 86,550 $ 85,101 $ 270,421 $ 254,472 Gross margin IMAX theater systems IMAX systems (2) $ 16,743 $ 13,109 $ 38,252 $ 34,831 Theater system maintenance 3,398 3,521 10,207 9,891 Joint revenue sharing arrangements (2) 10,980 12,130 44,716 46,816 31,121 28,760 93,175 91,538 Films Production and IMAX DMR (2) 12,448 13,929 52,398 55,642 Distribution (2) 258 15 (998) (201) Post-production 1,003 (48) 3,028 847 13,709 13,896 54,428 56,288 Other 69 (267) (251) (421) Total $ 44,899 $ 42,389 $ 147,352 $ 147,405 ___________ (1) The Company’s largest customer represented 11.2 % and 14.3 % of total revenues for the three and nine months ended September 30, 2016 , respectively ( 2015 — 17.6 % and 17.4 %, res pectively). (2) IMAX systems include marketing and commission costs of $ 0.8 million and $ 1.9 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 0.9 million and $ 1.8 million, respectively). Joint revenue sharing arrangements segment margins include advertising, marketing and commission co sts of $ 1.4 million and $ 2.9 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 1.3 million and $ 2.7 million, respectively). Production and DMR segment margins include marketing costs of $ 4.2 million and $ 11.7 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — $ 3.4 million and $ 8.3 million, respectively). Distribution segment margins include marketing expense of $ 0.6 million and $ 2.1 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — cost recovery of less than $ 0.1 million and cost recovery of $ 0.1 million, respectively). Geographic Information Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the re-mastered films. IMAX DMR revenue is generated through contractual relations hips with studios and other third parties and these may not be in the same geographical location as the theater. Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Revenue United States $ 28,139 $ 27,914 $ 96,276 $ 95,945 Canada 2,368 3,412 9,992 8,440 Greater China 29,736 27,513 84,797 71,427 Asia (excluding Greater China) 10,665 11,007 25,034 26,732 Western Europe 6,140 7,100 26,522 24,139 Russia & the CIS 2,397 1,705 7,684 9,510 Latin America 1,408 2,459 8,562 7,849 Rest of the World 5,697 3,991 11,554 10,430 Total $ 86,550 $ 85,101 $ 270,421 $ 254,472 No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) classificat ions comprises more than 10% of the total revenue.

Employees Pension and Postretir

Employees Pension and Postretirement Benefits	9 Months Ended
	Sep. 30, 2016
Employees Pension and Postretirement Benefits [Abstract]
Employees Pension and Postretirement Benefits	14. Employee's Pension and Postretirement Benefits Defined Benefit Plan The Company has an unfunded U.S. defined benefit pension plan (the “SERP”) covering Richard L. Gelfond, CEO of the Company. The following table provides disclosure of the pension obligation for the SERP: September 30, December 31, 2016 2015 Projected benefit obligation: Obligation, beginning of period $ 19,478 $ 19,405 Interest cost 196 253 Actuarial gain - (180) Obligation, end of period and unfunded status $ 19,674 $ 19,478 The following table provides disclosure of pension expense for the SERP: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Interest cost $ 65 $ 63 $ 196 $ 189 Pension expense $ 65 $ 63 $ 196 $ 189 No contributions are expected to be made for the SERP during the remainder of 2016 . The Company expects i nterest costs of $ 0.1 million to be recognized as a component of net periodic benefit cost during the remainder of 2016 . The accumulated benefit obligation for the SERP was $ 19.7 million at September 30, 2016 (December 31, 2015 — $ 19.5 million). The following benefit payments are expected to be made as per the current SERP assumptions and the terms of the SERP in each of the next 5 years, and in the aggregate: 2016 (three months remaining) $ - 2017 19,871 2018 - 2019 - 2020 - Thereafter - $ 19,871 The SERP assumptions are that Mr. Gelfond will receive a lump sum payment six months after retirement at the end of the current term of his employment agreement (December 31, 2016), although Mr. Gelfond has not informed the Company that he intends to retire at that time, and is curren tly in disc ussions regarding an extension of his employment agreement with the Company. Defined Contribution Pension Plan The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contr ibutions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums. During the three and nine months ended September 30, 2016 , the Company contributed and exp ensed an aggregate of $ 0.3 million and $ 0.9 million, respectively ( 2015 — $ 0.2 million and $ 0.8 million, respectively ) to its Canadian defined contribution plan and an aggregate of $ 0.1 million and $ 0.5 million, respectively ( 2015 — $ 0.2 million and $ 0.4 million, respectively ) to its defined contribution employee plan under Section 401(k) of the U.S. Internal Revenue Code. Postretirement Benefits - Executives The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, Chairman of the Company’s Board of Directors. The plan provides that the Company will maintain health benefits for Messrs. Gelfond and Wechsler until they become eligible for Medicare and, thereafter, the Company will provi de Medicare supplement coverage as selected by Messrs. Gelfond and Wechsler. The postretirement benefits obligation as at September 30, 2016 is $ 0.8 million (December 31, 2015 — $ 0.8 million). The Company has expensed less than $ 0.1 million and less than $0.1 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — less than $0.1 million and less than $0.1 million, respectively). The following benefit payments are expected to be made as per the current plan assumptions in each of the next 5 years: 2016 (three months remaining) $ 34 2017 54 2018 60 2019 66 2020 33 Thereafter 539 Total $ 786 Postretirement Benefits – Canadian Employees The Company has an unfunded postretirement plan for its Canadian employees upon meeting specific eligibility requirements. The Company will provide eligible participants, upon retirement, with health and welfare benefits. The postretirement benefits obligation as at September 30, 2016 is $ 1.9 million (December 31, 2015 — $ 1.8 million). The Company has expensed less than $ 0.1 million and less than $0.1 million for the three and nine months ended September 30, 2016 , respectively ( 2015 — less than $ 0.1 million and $0.1 million, respectively). The following benefit payments are expected to be made as p er the current plan assumptions in each of the next 5 years: 2016 (three months remaining) $ 96 2017 100 2018 108 2019 115 2020 117 Thereafter 1,330 Total $ 1,866

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2016
Financial Instruments [Abstract]
Financial Instruments	15. Financial Instruments Financial Instruments The Company maintains cash with various major financial institutions. The Company’s cash is invested with highly rated financial institutions. The Company’s accounts receivables and financing receivables are subject to credit risk. The Company’s accounts receivable and financing receivables are concentrated with the theater exhibition industry and film entertainment industry. To minimize the Company’s credit r isk, the Company retains title to underlying theater systems leased, performs initial and ongoing credit evaluations of its customers and makes ongoing provisions for its estimate of potentially uncollectible amounts. The Company believes it has adequately provided for related exposures surrounding receivables and contractual commitments. Fair Value Measurements The carrying values of the Company’s cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities due within one yea r approximate fair values due to the short-term maturity of these instruments. The Company’s other financial instruments are comprised of the following: As at September 30, 2016 As at December 31, 2015 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Cash and cash equivalents $ 218,104 $ 218,104 $ 317,449 $ 317,449 Net financed sales receivable $ 110,054 $ 110,260 $ 106,286 $ 108,184 Net investment in sales-type leases $ 8,843 $ 9,142 $ 10,945 $ 11,154 Available-for-sale investment $ 1,000 $ 1,012 $ 1,000 $ 997 Convertible loan receivable $ 1,000 $ 1,000 $ - $ - Foreign exchange contracts — designated forwards $ 7 $ 7 $ (4,423) $ (4,423) Borrowings under the Playa Vista Loan $ (28,167) $ (28,167) $ (29,667) $ (29,667) Cash and cash equivalents are comprised of cash and interest-bearing investments with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value (Level 1 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 an d December 31, 2015 , respectively. The estimated fair values of the net financed sales receivable and net investment in sales-type leases are estimated based on discounting future cash flows at currently available interest rates with comparable terms (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 and December 31, 2015 , respectively. The fair value of the Company’s available-for-sale investment is determined using quoted prices in act ive markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 and December 31, 2015 , respectively. The fair value of the Company’s convertible loan receivable approximates market value as at September 30, 2016 , as the loan was issued in the last month of the quarter (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy). The fair value of foreign currency derivatives is determined using quoted prices in active markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 and December 31, 2015 , respectively. These identical instruments are traded on a closed exchange. The carrying value of borrowings under the Playa Vista Loan approximates fair value as the interest rates offered under the Playa V ista Loan are close to September 30, 2016 market rates for the Company for debt of the same remaining maturities (Level 2 input in accordance with the Fair Value Measurements Topic of the FAS B ASC hierarchy) as at September 30, 2016 . There were no significant transfers between Level 1 and Level 2 during the nine months ended September 30, 2016 or 2015 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no transfe rs in or out of the Company’s level 3 assets during the nine months ended September 30, 2016 . Financing Receivables The Company’s net investment in leases and its net financed sale receivables are subject to the disclosure requirements of ASC 310 “Receivables”. Due to differing risk profiles of its net investment in leases and its net financed sales receivables, the Company views its net investment in leases and its net financed sale receivables as separate classe s of financing receivables. The Company does not aggregate financing receivables to assess impairment. The Company monitors the credit quality of each customer on a frequent basis through collections and aging analyses. The Company also holds meetings mon thly in order to identify credit concerns and whether a change in credit quality classification is required for the customer. A customer may improve in their credit quality classification once a substantial payment is made on overdue balances or the custom er has agreed to a payment plan with the Company and payments have commenced in accordance to the payment plan. The change in credit quality indicator is dependent upon management approval. The Company classifies its customers into four categories to indi cate the credit quality worthiness of its financing receivables for internal purposes only: Good standing — Theater continues to be in good standing with the Company as the client’s payments and reporting are up-to-date. Credit Watch — Theater operator has begun to demonstrate a delay in payments, and has been placed on the Company's credit watch list for continued monitoring, but active communication continues with the Company. Depending on the size of outstanding balance, length of time in arrears and other factors, transactions may need to be approved by management. These financing receivables are considered to be in better condition than those receivables related to theaters in the "Pre-approved transactions" category, but not in as good of condition as those receivables in "Good standing." Pre-approved transactions only — Theater operator is demonstrating a delay in payments with little or no communication with the Company. All service or shipments to the theater must be reviewed and approved by ma nagement. These financing receivables are considered to be in better condition than those receivables related to theaters in the "All transactions suspended" category, but not in as good of condition as those receivables in "Credit Watch." Depending on the individual facts and circumstances of each customer, finance income recognition may be suspended if management believes the receivable to be impaired. All transactions suspended — Theater is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater is classified as “All transactions suspended” the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped. The following table discloses the recorded investment in fin ancing receivables by credit quality indicator: As at September 30, 2016 As at December 31, 2015 Minimum Financed Minimum Financed Lease Sales Lease Sales Payments Receivables Total Payments Receivables Total In good standing $ 7,974 $ 108,375 $ 116,349 $ 10,252 $ 105,352 $ 115,604 Pre-approved transactions - 1,387 1,387 - 757 757 Transactions suspended 1,541 935 2,476 1,365 745 2,110 $ 9,515 $ 110,697 $ 120,212 $ 11,617 $ 106,854 $ 118,471 While recognition of finance income is suspended, payments received by a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a recovery of prov ision taken on the billed amount, if applicable, is recorded to the extent of the residual cash received. Once the collectibility issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of finance in come. The Company’s investment in financing receivables on nonaccrual status is as follows: As at September 30, 2016 As at December 31, 2015 Recorded Related Recorded Related Investment Allowance Investment Allowance Net investment in leases $ 1,541 $ (672) $ 1,365 $ (672) Net financed sales receivables 935 (643) 745 (568) Total $ 2,476 $ (1,315) $ 2,110 $ (1,240) The Company considers financing receivables with aging between 60-89 days as indications of theaters with potential collection concerns. The Company will begin to focus its review on these financing receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to review and assess collectibility on the theater’s past due accounts. Over 90 days past due is used by the Company as an indicator of potential impairment as invoices up to 90 days outstanding could be considered reasonable due to the time required for d ispute resolution or for the provision of further information or supporting documentation to the customer. The Company’s aged financing receivables are as follows: As at September 30, 2016 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 84 $ 81 $ 771 $ 936 $ 8,579 $ 9,515 $ (672) $ 8,843 Net financed sales receivables 2,038 883 2,489 5,410 105,287 110,697 (643) 110,054 Total $ 2,122 $ 964 $ 3,260 $ 6,346 $ 113,866 $ 120,212 $ (1,315) $ 118,897 As at December 31, 2015 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 840 $ 177 $ 446 $ 1,463 $ 10,154 $ 11,617 $ (672) $ 10,945 Net financed sales receivables 908 1,013 1,177 3,098 103,756 106,854 (568) 106,286 Total $ 1,748 $ 1,190 $ 1,623 $ 4,561 $ 113,910 $ 118,471 $ (1,240) $ 117,231 The Company’s recorded investm ent in past due financing receivables for which the Company continues to accrue finance income is as follows: As at September 30, 2016 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ 12 $ 53 $ 315 $ 380 $ 2,424 $ - $ 2,804 Net financed sales receivables 546 522 2,463 3,531 23,103 - 26,634 Total $ 558 $ 575 $ 2,778 $ 3,911 $ 25,527 $ - $ 29,438 As at December 31, 2015 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ 41 $ 47 $ 205 $ 293 $ 1,076 $ - $ 1,369 Net financed sales receivables 129 224 839 1,192 10,795 - 11,987 Total $ 170 $ 271 $ 1,044 $ 1,485 $ 11,871 $ - $ 13,356 The Company considers financing receivables to be impaired when it believes it to be probable that it will not recover the full amount of principal or i nterest owing under the arrangement. The Company uses its knowledge of the industry and economic trends, as well as its prior experiences to determine the amount recoverable for impaired financing receivables. The following table discloses information rega rding the Company’s impaired financing receivables: For the Three Months Ended September 30, 2016 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 748 $ 269 $ (643) $ 748 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 748 $ 269 $ (643) $ 748 $ - For the Three Months Ended September 30, 2015 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ - For the Nine Months Ended September 30, 2016 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 748 $ 269 $ (643) $ 674 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 748 $ 269 $ (643) $ 674 $ - For the Nine Months Ended September 30, 2015 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ - The Company’s activity in th e allowance for credit losses for the period and the Company’s recorded investment in financing receivables are as follows: Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Allowance for credit losses: Beginning balance $ 672 $ 643 $ 672 $ 568 Charge-offs - - - - Recoveries - - - - Provision - - - 75 Ending balance $ 672 $ 643 $ 672 $ 643 Ending balance: individually evaluated for impairment $ 672 $ 643 $ 672 $ 643 Financing receivables: Ending balance: individually evaluated for impairment $ 9,515 $ 110,697 $ 9,515 $ 110,697 Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Allowance for credit losses: Beginning balance $ 972 $ 494 $ 972 $ 494 Charge-offs - - - - Recoveries - - - - Provision - - - - Ending balance $ 972 $ 494 $ 972 $ 494 Ending balance: individually evaluated for impairment $ 972 $ 494 $ 972 $ 494 Financing receivables: Ending balance: individually evaluated for impairment $ 12,032 $ 103,418 $ 12,032 $ 103,418 Foreign Exchange Risk Management The Company is exposed to market risk from changes in foreign currency rate s. A majority portion of the Company’s revenues is denominated in U.S. dollars while a substantial portion of its costs and expenses is denominated in Canadian dollars. A portion of the net U.S. dollar cash flows of the Company is periodically converted to Canadian dollars to fund Canadian dollar expenses through the spot market. In China and Japan the Company has ongoing operating expenses related to its operations in Chinese Renminbi and Japanese yen, respectively. Net cash flows are converted to and from U.S. dollars through the spot market. The Company also has cash receipts under leases denominated in Chinese Renminbi, Japanese yen, Canadian dollars and Euros which are converted to U.S. dollars through the spot market. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company entered into a series of foreign currency forward contracts to manage the Company’s risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests at September 30, 2016 (the “Foreign Currency Hedges”), with settlement dates throughout 2016 and 2017 . Foreign currency derivatives are recognized and measured in the balance sheet at fair value. Changes in the fair value (gains or l osses) are recognized in the condensed consolidated statement s of operations except for derivatives designated and qualifying as foreign currency hedging instruments. For foreign currency hedging instruments, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in other comprehensive income and reclassified to the condensed consolidated statement s of operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the condensed c onsolidated statement s of operations. The Company currently does not hold any derivatives which are not designated as hedging instruments and therefore no gain or loss pertaining to an ineffective portion has been recognized. The following tabular disclos ures reflect the impact that derivative instruments and hedging activities have on the Company’s condensed consolidated financial statements: Notional value of foreign exchange contracts: September 30, December 31, 2016 2015 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 26,869 $ 30,710 Fair value of derivatives in foreign exchange contracts: September 30, December 31, Balance Sheet Location 2016 2015 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 734 $ - Accrued and other liabilities (727) (4,423) $ 7 $ (4,423) Derivatives in Foreign Currency Hedging relationships for the nine months ended September 30 : Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Foreign exchange contracts — Forwards Derivative (Loss) Gain Recognized in OCI (Effective Portion) $ (293) $ (2,309) $ 1,865 $ (4,983) Location of Derivative Loss Reclassified from AOCI Three Months Ended September 30, Nine Months Ended September 30, into Income (Effective Portion) 2016 2015 2016 2015 Foreign exchange contracts — Forwards Selling, general and administrative expenses $ (572) $ (1,045) $ (2,565) $ (2,196) The Company's estimated net amount of the existing gains as at September 30, 2016 is $0.1 million, which is expected to be reclassified to earnings within the next twelve months Investments in New Business Ventures The Company accounts for investments in new business ventures using the guidance of the FASB ASC 323 or FASB ASC 320, as appropriate. As at September 30, 2016 , the equity method of accounting is being utilized for an investment with a carrying value of $ nil (December 31, 2015 — $ 1.0 million). The Company’s accumulated losses in excess of its equity investment were $ 1.4 million as at September 30, 2016 , and are classified in Accrued and other liabilities. For the three months ended September 30, 2016 , gross revenues, cost of revenue and net loss for the Company’s investments were $ nil , $ 1.6 million and $ 1.5 million, respectively ( 2015 — $ nil , $ 1.9 million and $ 1.8 mill ion, respectively). For the nine months ended September 30, 2016 , gross revenues, cost of revenue and net loss for the Company’s investments were $ 0.3 millio n , $ 6.0 million and $ 5.6 million, respectively ( 2015 — $ nil , $ 6.4 million and $ 6.2 million, respectively). The Company has determined it is not the primary beneficiary of this VIE, and therefore this entity has not been consolidated. In the third quarter of 2016, the Company issued a convertible loan of $1.0 million to this entity with a term of 3 years with an annual effective interest rate of 5.0%. The instrument is classifi ed as an available-for- sale investment due to certain features that allow for conversion to common s tock in the entity in the event of certain triggers occurring. In addition, the Company has an investment in preferred stock of another business venture of $ 1.5 million which meets the criteria for classification as a debt secu rity under the FASB ASC 320 and is recorded at a fair value of $ nil at September 30, 2016 (December 31, 2015 — $ nil ). This investment was classified as an available-for-sale investment. Furthermore, the Company has an investment of $ 1.0 million (December 31, 2015 — $ 1.0 million) in the shares of an exchange traded fund. This investment is also classified as an available-for-sale investment. The Company has an investment of $ 2.5 million in the preferred shares of an enterprise which meet the criteria for classification as an equity security under FASB ASC 325. In the three and nine months ended September 30, 2016 , respectively, the Company recognized an other -than-temporary impairment of $nil and $0.2 million in the condensed consolidated statement s of operations (2015 — $nil and $0.4 million, respectively) . The total carrying value of investments in new business ventures at September 30, 2016 is $ 1.0 million (December 31, 2015 — $ 2.2 million) and is recorded in Other assets.

Non-Controlling Interests

Non-Controlling Interests	9 Months Ended
	Sep. 30, 2016
Temporary Equity Disclosure [Abstract]
Non-Controlling Interests [Text Block]	16. Non-Controlling Interests IMAX China Non-Controlling Interest On April 8, 2014, the Company announced sale and issuance of 20% of the shares of IMAX China to entities owned and controlled by CMC Capital Partners (“CMC”), an investment fund that is focused on media and entertainment, and FountainVest Partners (“FountainVest”), a China-focused private equity firm. The sale price for the interest was $80.0 million, and was paid by the investors in two equal installments on April 8, 2014 and February 10, 2015. On October 8, 2015, IMAX China completed the IMAX China IPO. Following the IMAX China IPO, the Company continues to indirectly own approximately 68.5% of IMAX China, which remains a consolidated subsidi ary of the Company. The following summarizes the movement of the non-controlling interest in shareholders’ equity, in the Company’s subsidiary for the nine months ended September 30, 2016 : Balance as at December 31, 2015 $ 49,959 Net income 8,015 Other comprehensive loss (1,415) Balance as at September 30, 2016 $ 56,559 Other Non-Controlling Interest In 2014, the Company announced the creation of the Film Fund to co-finance a portfolio of 10 original large-format films. The Film Fund, which is intended to be capitalized with up to $ 50.0 million, will finance an ongoing supply of original films that the Company believes will be more exciting and compelling than t raditional documentaries. The initial investment in the Film Fund was committed to by a third party in the amount of $ 25.0 million, with the possibility of contributing additional funds. The Company, which will contribute $ 9.0 million to the Film Fund over five years starting in 2014, anticipates the Film Fund will be self-perpetuating, with a portion of box office proceeds reinvested into the Film Fund to generate a continuous, steady flow of hi gh-quality documentary content. To date, the Film Fund invested $7.7 million toward the development of original films. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, ti tle and interest in the co-financed pictures. The following summarizes the movement of the non-controlling interest in temporary equity, in the Company’s subsidiary for the nine months ended September 30, 2016 : Balance as at December 31, 2015 $ 3,307 Net loss (614) Balance as at September 30, 2016 $ 2,693

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2016
Basis of Presentation and Condensed Consolidated Statements of Operations Supplemental Information [Abstract]
Basis of Accounting	All intercompany accounts and transactions, including all unrealized intercompany profits on trans actions with equity-accounted investees, have been eliminated. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. These interim financial state ments should be read in conjunction with the consolidated financial statements included in the Company’s 2015 Annual Report on Form 10-K for the year ended December 31, 2015 (“the 2015 Fo rm 10-K”) which should be consulted for a summary of the significant accounting policies utilized by the Company. These interim financial statements are prepared following accounting policies consistent with the Company’s financial statements for the year ended December 31, 2015 , except as noted below.
Variable interest entities	The condensed consolidated financial statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which the Company has identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. The nature of the Company’s business is such that the results of operations for the interim periods presented are not necessarily indicative of results to be expected for the fiscal year. In the opinion of management, the information contained herein reflects all normal and recurring adjustments necessary to make the re sults of operations for the interim periods a fair statement of such operations. The Company has evaluated its various variable interests to determine whether they are VIEs as required by the Consolidation Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC” or “Codification”). The Company has 11 film production companies that are VIEs. For five of the Company’s film production companies, the Company has determined that it is the primary beneficiary of these entities as the Company has the power to direct the activities of the respective VIE that most significantly impact the respective VIE’s economic performance and has the obligation to absorb losses of the VIE that could potentially be significant to the re spective VIE or the right to receive benefits from the respective VIE that could potentially be significant to the respective VIE. These consolidated production companies have total assets of $ 8.4 million (December 31, 2015 — $ 7.2 million) and total liabilities of $ 4.1 million as at September 30, 2016 (December 3 1, 2015 — $ 4.1 million). The majority of these consolidated assets are held by the IMAX Original Film Fund (the “Film Fund”) as described in note 16(b). For the other six film production companies which are VIEs, the Company did not consolidate these film entities since it does not have the power to direct activities and does not absorb the majority of the expected losses or expected residual returns. The Company equity accounts for these entities. As at September 30, 2016 , these six VIEs have total assets of $ 0.4 million (December 31, 2015 — $ 0.4 million) and total liabilities of $ 0.4 million (December 31, 2015 — $ 0.4 million). Earnings of the investees included in the Company’s condensed consolidated statemen t s of operations amounted to $nil and $nil for the three and nine months ended September 30, 2016 , respectively ( 2015 — $nil and $nil, respectively ). The carrying value of these investments in VIEs that are not consolidated is $nil at September 30, 2016 (December 31, 2015 — $nil). A loss in value of an inves tment other than a temporary decline is recognized as a charge to the condensed consolidated statement s of operations. The Company’s exposure, which is determined based on the level of funding contributed by the Company and the development stage of the resp ective film, is $nil at September 30, 2016 (December 31, 2015 — $nil).
Equity and Cost Method Investments Policy	The Company accounts for investments in new business ventures using the guidance of the F ASB ASC 323 “Investments – Equity Method and Joint Ventures” (“ASC 323”) or ASC 320 “Investments in Debt and Equity Securities” (“ASC 320”), as appropriate.
New Accounting Pronouncements Adopted	In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” (“ASU 2015-01”). Prior to the changes under ASU 2015-01, an entity was required to separately classify, present and disclose extraordinary events and transactions under the disclosure requirements of Subtopic 225-20, “Income Statement – Extraordinary and Unusual Items” (“Subtopic 225-20”). ASU 2015-01 eliminates from U.S. GAAP the concept of extraordinary items therefore such separate disclosure is no longer required in the Income Statement of an entity. For public companies, the amendments are effective for fiscal years, and interim periods wi thin those fiscal years, beginning after December 15, 2015. The amendments can be applied prospectively or retrospectively. The Company prospectively adopted the amendments under ASU 2015-01 on January 1, 2016. The adoption of the standard did not have an impact on the disclosures presented in the condensed consolidated statement of operations for the three and six months ended June 30, 2016 and 2015, respectively. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”). ASU 2015-02, changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities such as limited partnerships and similar entities, and variable interest entities that have free arrangements and related party relationships. Furthermore, all legal entities are subject to re-evaluation under the revised consolidation model. The amendments also provide a scope exception from consolidation guidance f or reporting entities with interest in legal entities that are required to comply with or operate in accordance with requirements that are similar to those in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds. For public com panies, the amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments can be applied retrospectively or using a modified retrospective approach by recording a cumulative-effe ct adjustment to equity as of the beginning of the fiscal year of adoption. The Company adopted the amendments under ASU 2015-02 retrospectively on January 1, 2016. The adoption of the standard did not have an impact on the Company’s condensed consolidated financial statements as there was no change to the entities currently consolidated by the Company. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ ASU 2016-09”). The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. ASU 2016-09 requires that the Company elect to account for forfeitures based on an estimate of the number of awards for which the requisite service period will not be rendered or to account for forfeitures as they occur. The Company elected to early adopt ASU 2016-09 during the second quarter of 2016 and to account for forfeitures as they occur. The impact from the adoption of the provisions related to forfeiture rates was reflected in the Company’s condensed consolidated financial statements on a modified retrospective basis resulting in a balance sheet reclass of $4.4 million decrease to Accumulated earnings, $ 0.9 million increase to Deferred income taxes and $5.3 million increase to Other equity. A recovery of stock-based compensation expense of $2.7 million for the nine month period ended September 30, 2016 was also recorded. Amendments related to accounting f or excess tax benefits have been adopted prospectively resulting in a tax benefit of $0.1 million for the nine months ended September 30, 2016, and amendments related to the condensed consolidated statement of cash flows have been adopted retrospectively. See Notes 11 and 12 for further discussion of the impact on the Company’s condensed consolidated financial statements from the adoption of ASU 2016-09.
Debt policy	In April 2015, th e FASB issued ASU No. 2015-03, “Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”), and in August 2015 issued ASU No. 2015-15, “Interest – Imputation of Interest (Subtopic 835-30): Pres entation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements” (“ASU 2015-15”). Under ASU 2015-03, debt issuance costs reported on the balance sheet will be reflected as a direct deduction from the related debt liab ility rather than as an asset. While ASU 2015-03 addresses costs related to term debt, ASU 2015-15 provides clarification regarding costs to secure revolving lines of credit, which are, at the outset, not associated with an outstanding borrowing. ASU 2015- 15 provides commentary that the U.S Securities and Exchange Commission (“SEC”) staff would not object to an entity deferring and presenting costs associated with line-of-credit arrangements as an asset and subsequently amortizing them ratably over the term of the revolving debt arrangement. For public companies, the amendments apply to annual periods beginning on or after December 15, 2015, and interim periods within those years and are to be applied retrospectively. The Company adopted these standards on J anuary 1, 2016. As at December 31, 2015, $0.4 million of unamortized debt issuance costs related to the Company’s loan to finance the construction of its Playa Vista facility were reclassified in the condensed consolidated balance sheet from Other assets t o Bank indebtedness. The Company will continue to defer and present the debt issuance cost related to its senior secured revolving credit facility in Other assets and amortize it ratably over the term of the agreement.
Accounting Pronouncements Not Yet Adopted	In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 20 16-01”). The purpose of the amendment is intended to provide users of financial statements with more useful information on the recognition, measurement, presentation, and disclosure of financial instruments. For public entities, the amendments in ASU 2016- 01 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-01 on its condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-0 2, “Leases (Topic 842)” (“ASU 2016-02”). The purpose of the amendment is to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. New disclosures will include qualitative and quantitative requirements to provide additional information about the amounts recorded in the financial statements. Lessor accounting will remain largely unchanged from current guidance, however ASU 2016-02 will provide improvements that are intended to align lessor accounting with the lessee model and with updated revenue recognition guidance. For public entities, the amendments in ASU 2016-02 are effective for interim and annual reporting periods beginning after December 15, 2018. The Company is curr ently assessing the impact of ASU 2016-02 on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-05, “Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relati onships” (“ASU 2016-05”). The amendments in ASU 2016-05 apply to all reporting entities for which there is a change in the counterparty to a derivative instrument that has been designated as a hedging instrument under Topic 815. The amendments clarify that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require de-designation of that hedging relationship provided that all other hedge accounting criteria (i ncluding those in paragraphs 815-20-35-14 through 35-18) continue to be met. For public entities, the amendments in ASU 2016-05 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU 2016-05 on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-07, “Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting” (“ASU 20 16-07”). The purpose of the amendment is to eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investmen t, results of operations, and retained earnings retroactively on a step-by step basis as if the equity method had been in effect during all previous periods that the investment had been held. For public entities, the amendments in ASU 2016-07 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU 2016-07 on its condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Con tracts with Customers (Topic 606): Principal versus Agent Considerations” (“ASU 2016-08”). The purpose of ASU 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. For public entities, the amendments in ASU 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-08 on its condensed consolidated financial statements. In April 2016, the FASB issued ASU No. 2016-10, “Rev enue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The purpose of ASU 2016-10 is to provide more detailed guidance in the following key areas: identifying performance obligations and licenses of intellectual property. For public entities, the amendments in ASU 2016-10 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-10 on its condensed consolidat ed financial statements. In May 2016, the FASB issued ASU No. 2016-11, “Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 pursuant to Staff announcements at the March 3, 2016 EITF Meeting” (“ASU 2016-11”). The purpose of ASU 2016-11 is to rescind from the FASB Accounting Standards Codification certain SEC paragraphs as a result of two SEC Staff Announcements at the March 3, 2016 meeting. For p ublic entities, the amendments in ASU 2016-11 related to Topic 605 are effective for interim and annual reporting periods beginning after December 15, 2017 and amendments related to Topic 815 are effective for interim and annual reporting periods beginning after December 15, 2015. The Company is currently assessing the impact of ASU 2016-11 related to topic 605 on its condensed consolidated financial statements. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 66 0): Narrow-Scope Improvements and Practical Expedients” (“ASU 2016-12”). The purpose of ASU 2016-12 is to clarify certain narrow aspects of Topic 66 0 such as assessing the collecti bility criterion, presentation of sales taxes and other similar taxes collec ted from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical correction. For public entities, the amendments in ASU 2016-12 are effective for interim and annual reporting periods beginnin g after December 15, 2017. The Company is currently assessing the impact of ASU 2016-12 on its condensed consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The purpose of ASU 2016-13 is to require a financial asset measured on the amortized cost basis to be presented at the net amount expected to be collected. Credit losses relating to available-for-sale de bt securities should be recorded through an allowance for credit losses. For public entities, the amendments in ASU 2016-13 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the imp act of ASU 2016-13 on its condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The purpose of ASU 20 16-15 is to reduce the diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. For public entities, the amendments in ASU 2016-15 are effective for interim and annual reporting perio ds beginning after December 15, 2017. The Company is currently assessing the impact of ASU 2016-15 on its condensed consolidated financial statements.
Commitments and Contingencies Policy	The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. In accordance with the Contingencies Topic of the FASB ASC, the Company will make a provision for a liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company believes it has adequate provisions for any su ch matters. The Company reviews these provisions in conjunction with any related provisions on assets related to the claims at least quarterly and adjusts these provisions to reflect the impacts of negotiations, settlements, rulings, advice of legal counse l and other pertinent information related to the case. Should developments in any of these matters outlined below cause a change in the Company’s determination as to an unfavorable outcome and result in the need to recognize a material provision, or, shoul d any of these matters result in a final adverse judgment or be settled for significant amounts, they could have a material adverse effect on the Company’s results of operations, cash flows, and financial position in the period or periods in which such a c hange in determination, settlement or judgment occurs.
Legal Costs Policy	The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred.
Commissions Expense Policy	The Company defers direct selling costs such as sales commissions and other amounts related to its sale and sales-type lease arrangements until the related revenue is recognized.
Collaborative Arrangements Policy	In a joint revenue sharing arrangement, the Co mpany receives a portion of a theater’s box-office and concession revenues, and in some cases a small upfront or initial payment, in exchange for placing a theater system at the theater operator’s venue. Under joint revenue sharing arrangements, the custom er has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to equipment under joint revenue sharing arrangements generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the term. The customer is requi red to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the theater systems commencing on the date specified in the arrangement’s shipping terms and ending on the date the theater systems are delivered back to the Company.
Film Costs Policy	In a typical IMAX DMR film arrangement, the Company will a bsorb its costs for the digital re-mastering and then recoup this cost from a percentage of the net box-office receipts of the film, which in recent years has ranged from 10-15%. The Company does not typically hold distribution rights or the copyright to t hese films.
Revenue Recognition Leases	The acco unting policy for the Company’s joint revenue sharing arrangements is disclosed in note 2(m) of the Company’s 2015 Form 10-K.
Films Revenue Recognition Policy	The accounting policy for the Company’s IMAX DMR arrangements is disclosed in note 2(m) of the Company’s 2015 Form 10-K. The accounting policies relating to co-produced film arrangements are disclosed in notes 2(a) and 2(m) of the Company’s 2015 Form 10-K.
Segment Reporting Policy	The accounting policies of the segments are the same as those described in note 2 to the audited consolidated financial statements included in the Company’s 2015 Form 10-K.
Fair Value of Financial Instruments Policy	Cash and cash equivalents are comprised of cash and interest-bearing investments with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value (Level 1 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 an d December 31, 2015 , respectively. The estimated fair values of the net financed sales receivable and net investment in sales-type leases are estimated based on discounting future cash flows at currently available interest rates with comparable terms (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 and December 31, 2015 , respectively. The fair value of the Company’s available-for-sale investment is determined using quoted prices in act ive markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 and December 31, 2015 , respectively. The fair value of the Company’s convertible loan receivable approximates market value as at September 30, 2016 , as the loan was issued in the last month of the quarter (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy). The fair value of foreign currency derivatives is determined using quoted prices in active markets (Level 2 input in accordance with the Fair Value Measurements Topic of the FASB ASC hierarchy) as at September 30, 2016 and December 31, 2015 , respectively. These identical instruments are traded on a closed exchange. The carrying value of borrowings under the Playa Vista Loan approximates fair value as the interest rates offered under the Playa V ista Loan are close to September 30, 2016 market rates for the Company for debt of the same remaining maturities (Level 2 input in accordance with the Fair Value Measurements Topic of the FAS B ASC hierarchy) as at September 30, 2016 .
Fair Value Transfer Policy	There were no significant transfers between Level 1 and Level 2 during the nine months ended September 30, 2016 or 2015 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.
Credit Risk Policy	The Company classifies its customers into four categories to indi cate the credit quality worthiness of its financing receivables for internal purposes only: Good standing — Theater continues to be in good standing with the Company as the client’s payments and reporting are up-to-date. Credit Watch — Theater operator has begun to demonstrate a delay in payments, and has been placed on the Company's credit watch list for continued monitoring, but active communication continues with the Company. Depending on the size of outstanding balance, length of time in arrears and other factors, transactions may need to be approved by management. These financing receivables are considered to be in better condition than those receivables related to theaters in the "Pre-approved transactions" category, but not in as good of condition as those receivables in "Good standing." Pre-approved transactions only — Theater operator is demonstrating a delay in payments with little or no communication with the Company. All service or shipments to the theater must be reviewed and approved by ma nagement. These financing receivables are considered to be in better condition than those receivables related to theaters in the "All transactions suspended" category, but not in as good of condition as those receivables in "Credit Watch." Depending on the individual facts and circumstances of each customer, finance income recognition may be suspended if management believes the receivable to be impaired. All transactions suspended — Theater is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater is classified as “All transactions suspended” the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped.
Condition for Company's policy to review and assess collectability on theater's past due accounts	The Company considers financing receivables to be impaired when it believes it to be probable that it will not recover the full amount of principal or i nterest owing under the arrangement. The Company uses its knowledge of the industry and economic trends, as well as its prior experiences to determine the amount recoverable for impaired financing receivables.
Derivatives policy	The Company is exposed to market risk from changes in foreign currency rate s. A majority portion of the Company’s revenues is denominated in U.S. dollars while a substantial portion of its costs and expenses is denominated in Canadian dollars. A portion of the net U.S. dollar cash flows of the Company is periodically converted to Canadian dollars to fund Canadian dollar expenses through the spot market. In China and Japan the Company has ongoing operating expenses related to its operations in Chinese Renminbi and Japanese yen, respectively. Net cash flows are converted to and from U.S. dollars through the spot market. The Company also has cash receipts under leases denominated in Chinese Renminbi, Japanese yen, Canadian dollars and Euros which are converted to U.S. dollars through the spot market. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company entered into a series of foreign currency forward contracts to manage the Company’s risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests at September 30, 2016 (the “Foreign Currency Hedges”), with settlement dates throughout 2016 and 2017 . Foreign currency derivatives are recognized and measured in the balance sheet at fair value. Changes in the fair value (gains or l osses) are recognized in the condensed consolidated statement s of operations except for derivatives designated and qualifying as foreign currency hedging instruments. For foreign currency hedging instruments, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in other comprehensive income and reclassified to the condensed consolidated statement s of operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the condensed c onsolidated statement s of operations. The Company currently does not hold any derivatives which are not designated as hedging instruments and therefore no gain or loss pertaining to an ineffective portion has been recognized.
ASU 2010-20	The Company considers financing receivables with aging between 60-89 days as indications of theaters with potential collection concerns. The Company will begin to focus its review on these financing receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to review and assess collectibility on the theater’s past due accounts. Over 90 days past due is used by the Company as an indicator of potential impairment as invoices up to 90 days outstanding could be considered reasonable due to the time required for d ispute resolution or for the provision of further information or supporting documentation to the customer.

Financing Receivables (Tables)

Financing Receivables (Tables)	9 Months Ended
	Sep. 30, 2016
Financing Receivables [Abstract]
Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales	Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales of theater systems are as follows: September 30, December 31, 2016 2015 Gross minimum lease payments receivable $ 11,341 $ 13,998 Unearned finance income (1,826) (2,381) Minimum lease payments receivable 9,515 11,617 Accumulated allowance for uncollectible amounts (672) (672) Net investment in leases 8,843 10,945 Gross financed sales receivables 148,358 146,232 Unearned finance income (37,661) (39,378) Financed sales receivables 110,697 106,854 Accumulated allowance for uncollectible amounts (643) (568) Net financed sales receivables 110,054 106,286 Total financing receivables $ 118,897 $ 117,231 Net financed sales receivables due within one year $ 21,260 $ 19,068 Net financed sales receivables due after one year $ 88,794 $ 87,218

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventories [Abstract]
Inventories	September 30, December 31, 2016 2015 Raw materials $ 32,662 $ 25,750 Work-in-process 4,215 2,628 Finished goods 14,138 10,375 $ 51,015 $ 38,753

Property Plant and Equipment (T

Property Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	As at September 30, 2016 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 216,670 $ 86,219 $ 130,451 Camera equipment 5,902 3,750 2,152 222,572 89,969 132,603 Assets under construction 14,890 - 14,890 Other property, plant and equipment Land 8,203 - 8,203 Buildings 68,974 14,306 54,668 Office and production equipment 40,587 21,237 19,350 Leasehold improvements 7,159 2,889 4,270 124,923 38,432 86,491 $ 362,385 $ 128,401 $ 233,984 As at December 31, 2015 Accumulated Net Book Cost Depreciation Value Equipment leased or held for use Theater system components $ 199,974 $ 74,568 $ 125,406 Camera equipment 5,393 3,368 2,025 205,367 77,936 127,431 Assets under construction 9,616 - 9,616 Other property, plant and equipment Land 8,203 - 8,203 Buildings 67,150 12,679 54,471 Office and production equipment 34,396 17,035 17,361 Leasehold improvements 3,512 2,327 1,185 113,261 32,041 81,220 $ 328,244 $ 109,977 $ 218,267

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Other Intangible Assets [Abstract]
Other Intangible Assets	As at September 30, 2016 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 11,181 $ 6,928 $ 4,253 Licenses and intellectual property 22,490 7,295 15,195 Other 14,023 3,866 10,157 $ 47,694 $ 18,089 $ 29,605 As at December 31, 2015 Accumulated Net Book Cost Amortization Value Patents and trademarks $ 10,399 $ 6,502 $ 3,897 Licenses and intellectual property 22,390 6,464 15,926 Other 11,878 2,751 9,127 $ 44,667 $ 15,717 $ 28,950
Other Intangible Assets - Future Amortization	As at September 30, 2016 , estimated amortization expense for each of the years ended December 31, are as follows: 2016 (three months remaining) $ 858 2017 3,270 2018 3,270 2019 3,270 2020 3,270

Credit Facility and Playa Vis29

Credit Facility and Playa Vista Loan (Tables)	9 Months Ended
	Sep. 30, 2016
Credit Facility and Playa Vista Construction Loan [Abstract]
Bank indebtedness	Bank indebtedness includes the following: September 30, December 31, 2016 2015 Playa Vista Loan $ 28,167 $ 29,667 Deferred charges on debt financing (361) (391) $ 27,806 $ 29,276
Construction loan principal payments	In accordance with the loan agreement, the Company is obligated to make payments on the principal of the loan as follows: 2016 (three months remaining) $ 500 2017 2,000 2018 2,000 2019 2,000 2020 2,000 Thereafter 19,667 $ 28,167

Contingencies and Guarantees (T

Contingencies and Guarantees (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments, Contingencies and Guarantees [Abstract]
Accrual for product warranties	September 30, December 31, 2016 2015 Balance at the beginning of period $ - $ 6 Warranty redemptions - (6) Warranties issued 15 - Revisions - - Balance at the end of period $ 15 $ -

Condensed Consolidated Statem31

Condensed Consolidated Statements of Cash Flows Supplemental Information (Tables)	9 Months Ended
	Sep. 30, 2016
Condensed Consolidated Statements of Cash Flows Supplemental Information [Abstract]
Changes in other non-cash operating assets and liabilities	Nine Months Ended September 30, 2016 2015 Decrease (increase) in: Accounts receivable $ 6,571 $ (12,048) Financing receivables (1,145) (9,932) Inventories (12,508) (18,904) Prepaid expenses (5,105) (2,159) Commissions and other deferred selling expenses 285 (206) Insurance recoveries 132 28 Other assets (1,299) (2,388) Increase (decrease) in: Accounts payable (6,616) 4,212 Accrued and other liabilities (1,991) (17,528) Deferred revenue (7,828) 17,892 $ (29,504) $ (41,033)
Cash payments	Nine Months Ended September 30, 2016 2015 Income taxes $ 20,822 $ 21,542 Interest $ 541 $ 302
Summary of depreciation and amortization	Nine Months Ended September 30, 2016 2015 Film assets $ 11,842 $ 11,917 Property, plant and equipment Joint revenue sharing arrangements 11,581 10,043 Other property, plant and equipment 7,355 5,635 Other intangible assets 2,368 2,354 Other assets 631 579 Deferred financing costs 402 663 $ 34,179 $ 31,191
Write downs, net of recoveries	Nine Months Ended September 30, 2016 2015 Accounts receivable $ 556 $ 709 Financing receivables 75 - Inventories 246 405 Film assets 1,000 - Property, plant and equipment 792 1,464 Impairment of investments 194 350 Other intangible assets 40 - $ 2,903 $ 2,928

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2016
Income Taxes [Abstract]
Income tax effect related to other comprehensive loss	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Unrealized change in cash flow hedging instruments $ 76 $ 606 $ (485) $ 1,309 Realized change in cash flow hedging instruments upon settlement (149) (274) (667) (577) Amortization of actuarial loss on postretirement benefit plan (4) - (14) - Foreign currency translation adjustments - 226 - 264 $ (77) $ 558 $ (1,166) $ 996

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2016
Capital Stock [Abstract]
Weighted average fair value of common share granted to employees and directors	The following assumptions were used to estimate the average fair value of t he stock options: Three Months Nine Months Ended September 30, Ended September 30, 2016 2015 2016 2015 Average risk-free interest rate 1.44% n/a 1.67% 1.97% Expected option life (in years) 4.44 - 4.88 n/a 4.44 - 5.24 3.55 - 5.76 Expected volatility 30% n/a 30% 30% Dividend yield 0% n/a 0% 0%
Option activity under the Stock Option Plan and the IMAX LTIP	The following table summarizes certain information in respect of option activity under the SOP and IMAX LTIP for the nine month periods ended September 30 : Weighted Average Exercise Number of Shares Price Per Share 2016 2015 2016 2015 Options outstanding, beginning of period 4,805,244 5,925,660 $ 27.03 $ 24.24 Granted 984,452 871,431 31.49 31.56 Exercised (268,516) (1,231,964) 20.54 19.35 Forfeited (45,024) (45,474) 28.03 28.26 Cancelled (2,483) - 33.80 - Options outstanding, end of period 5,473,673 5,519,653 28.14 26.45 Options exercisable, end of period 3,924,432 3,195,836 27.34 25.14
Restricted Stock Units activity under the IMAX LTIP	The following table summarizes cert ain information in respect of RSU activity under the IMAX LTIP for the nine months ended September 30 : Number of Awards Weighted Average Grant Date Fair Value Per Share 2016 2015 2016 2015 RSUs outstanding, beginning of period 973,637 595,834 $ 32.27 $ 27.13 Granted 465,968 337,557 31.70 34.39 Vested and settled (271,032) (192,077) 29.30 28.93 Forfeited (28,435) (19,499) 30.78 29.37 RSUs outstanding, end of period 1,140,138 721,815 32.78 29.99
Basic and diluted per-share computations	Reconciliations of the numerator and denominator of the basic and diluted per-share computations are comprised of the following: Three Months Nine Months Ended September 30, Ended September 30, 2016 2015 2016 2015 Net income attributable to common shareholders $ 2,525 $ 8,610 $ 19,843 $ 33,351 Less: Accretion charges associated with redeemable common stock - (263) - (747) Net income applicable to common shareholders $ 2,525 $ 8,347 $ 19,843 $ 32,604 Weighted average number of common shares (000's): Issued and outstanding, beginning of period 67,067 70,152 69,673 68,988 Weighted average number of shares issued (repurchased) during the period 23 (453) (1,620) 594 Weighted average number of shares used in computing basic income per share 67,090 69,699 68,053 69,582 Assumed exercise of stock options and RSUs, net of shares assumed repurchased 656 1,161 668 1,520 Weighted average number of shares used in computing diluted income per share 67,746 70,860 68,721 71,102
Movement of Shareholders' Equity	The following summarizes the movement of Shareholders’ Equity attributable to common shareholde rs for the nine months ended September 30, 2016 : Balance as at December 31, 2015 $ 624,791 Net income attributable to common shareholders 19,843 Adjustments to capital stock: Cash received from the issuance of common shares 5,514 Issuance of common shares for vested RSUs 1,121 Fair value of stock options exercised at the grant date 2,104 Average carrying value of repurchased and retired common shares (21,220) Share held in treasury (6) Adjustments to other equity: Employee stock options granted 10,092 Non-employee stock options granted and vested 30 Fair value of stock options exercised at the grant date (2,104) RSUs granted 12,242 RSUs vested (8,793) Stock exercised from treasury shares (1,216) Cash received from the issuance of common shares in excess of par value 1,682 Adjustments to accumulated deficit: Common shares repurchased and retired (79,158) Adjustments to accumulated other comprehensive loss: Unrealized net gain from cash flow hedging instruments 1,865 Realization of cash flow hedging net loss upon settlement 2,565 Foreign currency translation adjustments (434) Amortization of actuarial loss on postretirement benefit plan 51 Tax effect of movement in other comprehensive income (1,166) Balance as at September 30, 2016 $ 567,803

Segmented Information (Tables)

Segmented Information (Tables)	9 Months Ended
	Sep. 30, 2016
Segmented Information [Abstract]
Inter-segment revenue	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Revenue (1) IMAX theater systems IMAX systems $ 25,687 $ 30,153 $ 70,508 $ 64,632 Theater system maintenance 10,293 9,337 30,031 27,345 Joint revenue sharing arrangements 19,698 19,797 66,940 67,259 55,678 59,287 167,479 159,236 Films Production and IMAX DMR 21,549 20,865 78,767 75,144 Distribution 2,092 967 3,345 3,513 Post-production 2,327 761 6,436 5,259 25,968 22,593 88,548 83,916 Other 4,904 3,221 14,394 11,320 Total $ 86,550 $ 85,101 $ 270,421 $ 254,472 Gross margin IMAX theater systems IMAX systems (2) $ 16,743 $ 13,109 $ 38,252 $ 34,831 Theater system maintenance 3,398 3,521 10,207 9,891 Joint revenue sharing arrangements (2) 10,980 12,130 44,716 46,816 31,121 28,760 93,175 91,538 Films Production and IMAX DMR (2) 12,448 13,929 52,398 55,642 Distribution (2) 258 15 (998) (201) Post-production 1,003 (48) 3,028 847 13,709 13,896 54,428 56,288 Other 69 (267) (251) (421) Total $ 44,899 $ 42,389 $ 147,352 $ 147,405
Geographic Information	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Revenue United States $ 28,139 $ 27,914 $ 96,276 $ 95,945 Canada 2,368 3,412 9,992 8,440 Greater China 29,736 27,513 84,797 71,427 Asia (excluding Greater China) 10,665 11,007 25,034 26,732 Western Europe 6,140 7,100 26,522 24,139 Russia & the CIS 2,397 1,705 7,684 9,510 Latin America 1,408 2,459 8,562 7,849 Rest of the World 5,697 3,991 11,554 10,430 Total $ 86,550 $ 85,101 $ 270,421 $ 254,472

Employees Pension and Postret35

Employees Pension and Postretirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Amounts accrued	The following table provides disclosure of the pension obligation for the SERP: September 30, December 31, 2016 2015 Projected benefit obligation: Obligation, beginning of period $ 19,478 $ 19,405 Interest cost 196 253 Actuarial gain - (180) Obligation, end of period and unfunded status $ 19,674 $ 19,478
SERP Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Pension Expense	The following table provides disclosure of pension expense for the SERP: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Interest cost $ 65 $ 63 $ 196 $ 189 Pension expense $ 65 $ 63 $ 196 $ 189
Schedule of expected benefit payments	The following benefit payments are expected to be made as per the current SERP assumptions and the terms of the SERP in each of the next 5 years, and in the aggregate: 2016 (three months remaining) $ - 2017 19,871 2018 - 2019 - 2020 - Thereafter - $ 19,871
Postretirement Benefits Executives [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of expected benefit payments	The following benefit payments are expected to be made as per the current plan assumptions in each of the next 5 years: 2016 (three months remaining) $ 34 2017 54 2018 60 2019 66 2020 33 Thereafter 539 Total $ 786
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of expected benefit payments	The following benefit payments are expected to be made as p er the current plan assumptions in each of the next 5 years: 2016 (three months remaining) $ 96 2017 100 2018 108 2019 115 2020 117 Thereafter 1,330 Total $ 1,866

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Financial Instruments [Abstract]
Fair Value of Financial Instruments	The carrying values of the Company’s cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities due within one yea r approximate fair values due to the short-term maturity of these instruments. The Company’s other financial instruments are comprised of the following: As at September 30, 2016 As at December 31, 2015 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Cash and cash equivalents $ 218,104 $ 218,104 $ 317,449 $ 317,449 Net financed sales receivable $ 110,054 $ 110,260 $ 106,286 $ 108,184 Net investment in sales-type leases $ 8,843 $ 9,142 $ 10,945 $ 11,154 Available-for-sale investment $ 1,000 $ 1,012 $ 1,000 $ 997 Convertible loan receivable $ 1,000 $ 1,000 $ - $ - Foreign exchange contracts — designated forwards $ 7 $ 7 $ (4,423) $ (4,423) Borrowings under the Playa Vista Loan $ (28,167) $ (28,167) $ (29,667) $ (29,667)
Recorded Investment in Financing Receivables	The following table discloses the recorded investment in fin ancing receivables by credit quality indicator: As at September 30, 2016 As at December 31, 2015 Minimum Financed Minimum Financed Lease Sales Lease Sales Payments Receivables Total Payments Receivables Total In good standing $ 7,974 $ 108,375 $ 116,349 $ 10,252 $ 105,352 $ 115,604 Pre-approved transactions - 1,387 1,387 - 757 757 Transactions suspended 1,541 935 2,476 1,365 745 2,110 $ 9,515 $ 110,697 $ 120,212 $ 11,617 $ 106,854 $ 118,471
Investment In Financing Receivables On Nonaccrual Status	The Company’s investment in financing receivables on nonaccrual status is as follows: As at September 30, 2016 As at December 31, 2015 Recorded Related Recorded Related Investment Allowance Investment Allowance Net investment in leases $ 1,541 $ (672) $ 1,365 $ (672) Net financed sales receivables 935 (643) 745 (568) Total $ 2,476 $ (1,315) $ 2,110 $ (1,240)
Aging of Financing Receivables	The Company’s aged financing receivables are as follows: As at September 30, 2016 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 84 $ 81 $ 771 $ 936 $ 8,579 $ 9,515 $ (672) $ 8,843 Net financed sales receivables 2,038 883 2,489 5,410 105,287 110,697 (643) 110,054 Total $ 2,122 $ 964 $ 3,260 $ 6,346 $ 113,866 $ 120,212 $ (1,315) $ 118,897 As at December 31, 2015 Related Recorded Accrued Billed Unbilled Total Investment and 30-89 Financing Recorded Recorded Related Net of Current Days 90+ Days Receivables Investment Investment Allowances Allowances Net investment in leases $ 840 $ 177 $ 446 $ 1,463 $ 10,154 $ 11,617 $ (672) $ 10,945 Net financed sales receivables 908 1,013 1,177 3,098 103,756 106,854 (568) 106,286 Total $ 1,748 $ 1,190 $ 1,623 $ 4,561 $ 113,910 $ 118,471 $ (1,240) $ 117,231
Financing receivables continues to accrue finance income	The Company’s recorded investm ent in past due financing receivables for which the Company continues to accrue finance income is as follows: As at September 30, 2016 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ 12 $ 53 $ 315 $ 380 $ 2,424 $ - $ 2,804 Net financed sales receivables 546 522 2,463 3,531 23,103 - 26,634 Total $ 558 $ 575 $ 2,778 $ 3,911 $ 25,527 $ - $ 29,438 As at December 31, 2015 Related Recorded Accrued Billed Unbilled Investment and Financing Recorded Related Past Due Current 30-89 Days 90+ Days Receivables Investment Allowance and Accruing Net investment in leases $ 41 $ 47 $ 205 $ 293 $ 1,076 $ - $ 1,369 Net financed sales receivables 129 224 839 1,192 10,795 - 11,987 Total $ 170 $ 271 $ 1,044 $ 1,485 $ 11,871 $ - $ 13,356
Impaired financing receivables	The following table discloses information rega rding the Company’s impaired financing receivables: For the Three Months Ended September 30, 2016 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 748 $ 269 $ (643) $ 748 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 748 $ 269 $ (643) $ 748 $ - For the Three Months Ended September 30, 2015 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ - For the Nine Months Ended September 30, 2016 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 748 $ 269 $ (643) $ 674 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 748 $ 269 $ (643) $ 674 $ - For the Nine Months Ended September 30, 2015 Average Interest Recorded Unpaid Related Recorded Income Investment Principal Allowance Investment Recognized Recorded investment for which there is a related allowance: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ - Recorded investment for which there is no related allowance: Net financed sales receivables - - - - - Total recorded investment in impaired loans: Net financed sales receivables $ 525 $ 53 $ (494) $ 525 $ -
Allowance for credit losses and investment in financing receivables	The Company’s activity in th e allowance for credit losses for the period and the Company’s recorded investment in financing receivables are as follows: Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Allowance for credit losses: Beginning balance $ 672 $ 643 $ 672 $ 568 Charge-offs - - - - Recoveries - - - - Provision - - - 75 Ending balance $ 672 $ 643 $ 672 $ 643 Ending balance: individually evaluated for impairment $ 672 $ 643 $ 672 $ 643 Financing receivables: Ending balance: individually evaluated for impairment $ 9,515 $ 110,697 $ 9,515 $ 110,697 Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Allowance for credit losses: Beginning balance $ 972 $ 494 $ 972 $ 494 Charge-offs - - - - Recoveries - - - - Provision - - - - Ending balance $ 972 $ 494 $ 972 $ 494 Ending balance: individually evaluated for impairment $ 972 $ 494 $ 972 $ 494 Financing receivables: Ending balance: individually evaluated for impairment $ 12,032 $ 103,418 $ 12,032 $ 103,418
Notional amount of derivative	Notional value of foreign exchange contracts: September 30, December 31, 2016 2015 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 26,869 $ 30,710
Fair value of foreign exchange contracts	Fair value of derivatives in foreign exchange contracts: September 30, December 31, Balance Sheet Location 2016 2015 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 734 $ - Accrued and other liabilities (727) (4,423) $ 7 $ (4,423)
Derivatives in Foreign Currency Hedging relationships	Derivatives in Foreign Currency Hedging relationships for the nine months ended September 30 : Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Foreign exchange contracts — Forwards Derivative (Loss) Gain Recognized in OCI (Effective Portion) $ (293) $ (2,309) $ 1,865 $ (4,983) Location of Derivative Loss Reclassified from AOCI Three Months Ended September 30, Nine Months Ended September 30, into Income (Effective Portion) 2016 2015 2016 2015 Foreign exchange contracts — Forwards Selling, general and administrative expenses $ (572) $ (1,045) $ (2,565) $ (2,196)

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	9 Months Ended
	Sep. 30, 2016
IMAX China Noncontrolling Interest
Non-controlling Interests
Non-controlling Interests	Balance as at December 31, 2015 $ 49,959 Net income 8,015 Other comprehensive loss (1,415) Balance as at September 30, 2016 $ 56,559
Other Noncontrolling Interest [Member]
Non-controlling Interests
Non-controlling Interests	Balance as at December 31, 2015 $ 3,307 Net loss (614) Balance as at September 30, 2016 $ 2,693

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Basis of Presentation (Textuals) [Abstract]
Number Of Variable Interest Entities			11
Number Of Variable Interest Entities Primary Beneficiary			5
Number Of Variable Interest Entities Not A Primary Beneficiary			6
Variable interest entity, non-consolidated, Assets	$ 0.4		$ 0.4
Variable interest entity, non-consolidated, Liabilities	0.4		0.4
Variable Interest Entity, Primary Beneficiary [Member]
Basis of Presentation (Textuals) [Abstract]
Variable interest entity, consolidated, Assets	8.4		8.4		$ 7.2
Variable interest entity, consolidated, Liabilities	4.1		4.1		4.1
Variable Interest Entity, Not Primary Beneficiary [Member]
Basis of Presentation (Textuals) [Abstract]
Variable interest entity, non-consolidated, Assets	0.4		0.4		0.4
Variable interest entity, non-consolidated, Liabilities	0.4		0.4		0.4
Earnings of the investees	0	$ 0	0	$ 0
Carrying value of film production company VIEs	0		0		0
Loss exposure	$ 0		$ 0		$ 0

New Accounting Standards And 39

New Accounting Standards And Accounting Changes (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles
Deferred charges on debt financing			$ 391
Accumulated earnings relcass due to adoption of ASU 2016-09		$ 4,400
Deferred tax asset reclass due to adoption of ASU 2016-09		900
Other equity reclass due to adoption of ASU 2016-09		5,300
Stock-based compensation expense recovery due to adoption of ASU 2016-09		2,700
Excess tax benefit due to adoption of ASU 2016-09	$ 0	$ 100

Financing Receivables (Details)

Financing Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Financing receivables, consisting of net investment in sales-type leases and receivables from financed sales
Gross minimum lease payments receivable	$ 11,341	$ 13,998
Unearned finance income	(1,826)	(2,381)
Minimum lease payments receivable	9,515	11,617
Accumulated allowance for uncollectible amounts	(672)	(672)
Net investment in leases	8,843	10,945
Gross financed sales receivables	148,358	146,232
Unearned finance income	(37,661)	(39,378)
Financed sales receivables	110,697	106,854
Accumulated allowance for uncollectible amounts	(643)	(568)
Net financed sales receivables	110,054	106,286
Total financing receivables	118,897	117,231
Net financed sales receivables due within one year	21,260	19,068
Net financed sales receivables due after one year	$ 88,794	$ 87,218

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventories
Raw materials	$ 32,662	$ 25,750
Work-in-process	4,215	2,628
Finished goods	14,138	10,375
Total	$ 51,015	$ 38,753

Property Plant and Equipment (D

Property Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Property, plant and equipment
Cost	$ 362,385	$ 328,244
Accumulated Depreciation	128,401	109,977
Net Book Value	233,984	218,267
Equipment leased or held for use [Member]
Property, plant and equipment
Cost	222,572	205,367
Accumulated Depreciation	89,969	77,936
Net Book Value	132,603	127,431
Theater System Components [Member]
Property, plant and equipment
Cost	216,670	199,974
Accumulated Depreciation	86,219	74,568
Net Book Value	130,451	125,406
Camera Equipment [Member]
Property, plant and equipment
Cost	5,902	5,393
Accumulated Depreciation	3,750	3,368
Net Book Value	2,152	2,025
Assets Under Construction [Member]
Property, plant and equipment
Cost	14,890	9,616
Accumulated Depreciation	0	0
Net Book Value	14,890	9,616
Other property, plant and equipment [Member]
Property, plant and equipment
Cost	124,923	113,261
Accumulated Depreciation	38,432	32,041
Net Book Value	86,491	81,220
Land [Member]
Property, plant and equipment
Cost	8,203	8,203
Accumulated Depreciation	0	0
Net Book Value	8,203	8,203
Buildings [Member]
Property, plant and equipment
Cost	68,974	67,150
Accumulated Depreciation	14,306	12,679
Net Book Value	54,668	54,471
Office and Production Equipment [Member]
Property, plant and equipment
Cost	40,587	34,396
Accumulated Depreciation	21,237	17,035
Net Book Value	19,350	17,361
Leasehold Improvements [Member]
Property, plant and equipment
Cost	7,159	3,512
Accumulated Depreciation	2,889	2,327
Net Book Value	$ 4,270	$ 1,185

Other Intangible Assets (Detail

Other Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Other Intangible Assets
Other Intangible Assets, Cost	$ 47,694	$ 44,667
Other Intangible Assets, Accumulated Amortization	18,089	15,717
Other Intangible Assets, Net Book Value	29,605	28,950
Patents and Trademarks [Member]
Other Intangible Assets
Other Intangible Assets, Cost	11,181	10,399
Other Intangible Assets, Accumulated Amortization	6,928	6,502
Other Intangible Assets, Net Book Value	4,253	3,897
Licenses and Intellectual Property [Member]
Other Intangible Assets
Other Intangible Assets, Cost	22,490	22,390
Other Intangible Assets, Accumulated Amortization	7,295	6,464
Other Intangible Assets, Net Book Value	15,195	15,926
Other [Member]
Other Intangible Assets
Other Intangible Assets, Cost	14,023	11,878
Other Intangible Assets, Accumulated Amortization	3,866	2,751
Other Intangible Assets, Net Book Value	$ 10,157	$ 9,127

Credit Facility and Playa Vis44

Credit Facility and Playa Vista Loan (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Bank indebtedness [Line Items]
Deferred charges on debt financing		$ (391)
Total bank indebtedness	$ 27,806	29,276
Playa Vista Loan [Member]
Bank indebtedness [Line Items]
Playa Vista Loan	28,167	29,667
Deferred charges on debt financing	(361)	(391)
Total bank indebtedness	27,806	29,276
Playa Vista loan principal payments
2016 (three months remaining)	500
2,017	2,000
2,018	2,000
2,019	2,000
2,020	2,000
Thereafter	19,667
Playa Vista Loan	$ 28,167	$ 29,667

Contingencies and Guarantees (D

Contingencies and Guarantees (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Accrual for product warranties
Balance at the beginning of period	$ 0	$ 6
Warranty redemptions	0	(6)
Warranties issued	15	0
Revisions	0	0
Balance at the end of period	$ 15	$ 0

Condensed Consolidated Statem46

Condensed Consolidated Statement of Operations Supplemental Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)yrFilmexhibitorTheaters	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)yrFilmexhibitorTheaters	Sep. 30, 2015USD ($)Film
Selling Expenses
Deferred direct selling costs and direct advertising and marketing included in costs and expenses applicable to revenues-equipment and product sales	$ 1,300	$ 1,300	$ 3,000	$ 2,800
Film exploitation costs, including advertising and marketing included in costs and expenses applicable to revenues-services	4,800	3,400	13,800	8,200
Commissions recognized as cost and expenses included in costs and expenses applicable to revenues-rentals	600	300	900	500
Direct advertising and marketing costs included in costs and expenses applicable to revenues-rentals	400	600	1,000	1,200
Foreign Exchange
Foreign exchange translation (loss) gain related to monetary assets and liabilities	$ (200)	(500)	$ (100)	(1,500)
Collaborative Arrangements
Total number of exhibitors under joint revenue sharing agreements | exhibitor	49		49
Total number of theater systems under joint revenue sharing agreements | Theaters	981		981
Total number of operating theaters under joint revenue sharing agreement | Theaters	592		592
Amounts attributable to transactions arising between the company and its customers under joint revenue sharing arrangements	$ 19,700	19,800	$ 66,900	$ 67,300
IMAX DMR films exhibited in the period | Film			48	48
Amounts attributable to transactions arising between the company and its customers under IMAX DMR arrangements	$ 21,549	20,865	$ 78,767	$ 75,144
Number of significant co-produced film arrangement | Film	1		1
Number of other co-produced film arrangements | Film	5		5
Variable interest entity, non-consolidated, Assets	$ 400		$ 400
Variable interest entity, non-consolidated, Liabilities	400		400
Amounts attributable to transactions between the company and other parties involved in the production of films included in cost and expense	$ 500	$ 300	$ 1,000	$ 1,400
Minimum [Member]
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements | yr	10		10
Percentage of the gross box-office receipts of the film, minimum for recovering digital re-mastering cost	10.00%		10.00%
Maximum [Member]
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements			longer
Percentage of the gross box-office receipts of the film, maximum for recovering digital re-mastering cost	15.00%		15.00%

Condensed Consolidated Statem47

Condensed Consolidated Statements of Cash Flows Supplemental Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Decrease (increase) in:
Accounts receivable	$ 6,571	$ (12,048)
Financing receivables	(1,145)	(9,932)
Inventories	(12,508)	(18,904)
Prepaid expenses	(5,105)	(2,159)
Commissions and other deferred selling expenses	285	(206)
Insurance recoveries	132	28
Other assets	(1,299)	(2,388)
Increase (decrease) in:
Accounts payable	(6,616)	4,212
Accrued and other Liabilities	(1,991)	(17,528)
Deferred revenue	(7,828)	17,892
Changes in other non-cash operating assets and liabilities	(29,504)	(41,033)
Cash payments
Income taxes	20,822	21,542
Interest	$ 541	$ 302

Receivable Provisions Net of Re

Receivable Provisions Net of Recoveries (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Receivable Provisions, Net of Recoveries [Abstract]
Receivable provisions, net of recoveries	$ 275	$ 361	$ 631	$ 709

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Unrealized change in cash flow hedging instruments	$ 76	$ 606	$ (485)	$ 1,309
Realized change in cash flow hedging instruments upon settlement	(149)	(274)	(667)	(577)
Amortization of actuarial loss on postretirement benefit plan	(4)	0	(14)	0
Foreign currency translation adjustments	0	226	0	264
Income tax effect on other comprehensive (loss) income	$ (77)	$ 558	$ (1,166)	$ 996

Capital Stock (Details)

Capital Stock (Details) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Weighted average fair value of common share granted to employees and directors
Average risk-free interest rate	1.44%		1.67%	1.97%
Average risk-free interest rate		n/a
Expected option life (in years)		n/a
Expected volatility	30.00%		30.00%	30.00%
Expected volatility		n/a
Dividend yield	0.00%		0.00%	0.00%
Dividend yield		n/a
Minimum [Member]
Weighted average fair value of common share granted to employees and directors
Expected option life (in years)	4 years 5 months 8 days		4 years 5 months 8 days	3 years 6 months 18 days
Maximum [Member]
Weighted average fair value of common share granted to employees and directors
Expected option life (in years)	4 years 10 months 17 days		5 years 2 months 26 days	5 years 9 months 4 days

Segmented Information (Details)

Segmented Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues
Revenues		$ 86,550	$ 85,101	$ 270,421	$ 254,472
Gross margins
Gross margins		44,899	42,389	147,352	147,405
IMAX theater systems total [Member]
Revenues
Revenues	[1]	55,678	59,287	167,479	159,236
Gross margins
Gross margins		31,121	28,760	93,175	91,538
IMAX systems [Member]
Revenues
Revenues	[1]	25,687	30,153	70,508	64,632
Gross margins
Gross margins	[2]	16,743	13,109	38,252	34,831
Theater system maintenance [Member]
Revenues
Revenues	[1]	10,293	9,337	30,031	27,345
Gross margins
Gross margins		3,398	3,521	10,207	9,891
Joint revenue sharing arrangements [Member]
Revenues
Revenues	[1]	19,698	19,797	66,940	67,259
Gross margins
Gross margins	[2]	10,980	12,130	44,716	46,816
Films Total [Member]
Revenues
Revenues	[1]	25,968	22,593	88,548	83,916
Gross margins
Gross margins		13,709	13,896	54,428	56,288
Production and IMAX DMR [Member]
Revenues
Revenues	[1]	21,549	20,865	78,767	75,144
Gross margins
Gross margins	[2]	12,448	13,929	52,398	55,642
Distribution [Member]
Revenues
Revenues	[1]	2,092	967	3,345	3,513
Gross margins
Gross margins	[2]	258	15	(998)	(201)
Post-production [Member]
Revenues
Revenues	[1]	2,327	761	6,436	5,259
Gross margins
Gross margins		1,003	(48)	3,028	847
Other [Member]
Revenues
Revenues	[1]	4,904	3,221	14,394	11,320
Gross margins
Gross margins		$ 69	$ (267)	$ (251)	$ (421)
[1]	The Company’s largest customer represented 11.2% and 14.3% of total revenues for the three and nine months ended September 30, 2016, respectively (2015 — 17.6% and 17.4%, respectively).
[2]	IMAX systems include marketing and commission costs of $0.8 million and $1.9 million for the three and nine months ended September 30, 2016, respectively (2015 — $0.9 million and $1.8 million, respectively). Joint revenue sharing arrangements segment margins include advertising, marketing and commission costs of $1.4 million and $2.9 million for the three and nine months ended September 30, 2016, respectively (2015 — $1.3 million and $2.7 million, respectively). Production and DMR segment margins include marketing costs of $4.2 million and $11.7 million for the three and nine months ended September 30, 2016, respectively (2015 — $3.4 million and $8.3 million, respectively). Distribution segment margins include marketing expense of $0.6 million and $2.1 million for the three and nine months ended September 30, 2016, respectively (2015 — cost recovery of less than $0.1 million and cost recovery of $0.1 million, respectively).

Employees Pension and Postret52

Employees Pension and Postretirement Benefits (Details) - Pension Plans, Defined Benefit [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Amounts Accrued
Obligation, beginning of period			$ 19,478	$ 19,405	$ 19,405
Interest cost	$ 65	$ 63	196	189	253
Actuarial gain			0		(180)
Obligation, end of period and unfunded status	19,674		19,674		19,478
Pension Expense
Interest cost	65	63	196	189	$ 253
Pension expense	$ 65	$ 63	$ 196	$ 189

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Other Financial Instrument
Cash and cash equivalents	$ 218,104	$ 317,449	$ 117,361	$ 106,503
Net financed sales receivable	110,054	106,286
Net investment in sales-type leases	8,843	10,945
Convertible loan receivable	1,000
Foreign exchange contracts - designated forwards	7	(4,423)
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	218,104	317,449
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivable	110,054	106,286
Net investment in sales-type leases	8,843	10,945
Available-for-sale investment	1,000	1,000
Convertible loan receivable	1,000	0
Borrowings under the Playa Vista Loan	(28,167)	(29,667)
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts - designated forwards	7	(4,423)
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	218,104	317,449
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivable	110,260	108,184
Net investment in sales-type leases	9,142	11,154
Available-for-sale investment	1,012	997
Convertible loan receivable	1,000	0
Borrowings under the Playa Vista Loan	(28,167)	(29,667)
Estimate of Fair Value, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts - designated forwards	$ 7	$ (4,423)

Non-Controlling Interests (Deta

Non-Controlling Interests (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Non-controlling Interests
Issuance of subsidiary shares to non-controlling interests - private offering			$ 0	$ 40,000
Share issuance costs from the issuance of subsidiary shares to a non-controlling interest			0	(2,000)
Net income (loss)	$ 1,859	$ 1,904	7,401	$ 5,028
IMAX China Noncontrolling Interest
Non-controlling Interests
Balance as at December 31, 2015			49,959
Net income (loss)			8,015
Other comprehensive loss			(1,415)
Balance as at September 30, 2016	56,559		56,559
Other Noncontrolling Interest [Member]
Non-controlling Interests
Balance as at December 31, 2015			3,307
Net income (loss)			(614)
Balance as at September 30, 2016	$ 2,693		$ 2,693

Financing Receivables (Details

Financing Receivables (Details Textuals)	Sep. 30, 2016	Dec. 31, 2015
Financing Receivables (Textuals) [Abstract]
Financed sale receivables, Weighted average effective interest rate	9.20%	9.40%

Inventories (Details Textuals)

Inventories (Details Textuals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Inventories (Textuals) [Abstract]
Finished goods inventory with title passed to customer	$ 5,100		$ 5,100		$ 5,400
Write-downs (recoveries) for excess and obsolete inventory	$ (15)	$ (59)	$ 246	$ 405

Other Intangible Assets (Deta57

Other Intangible Assets (Details 1) $ in Thousands	Sep. 30, 2016USD ($)
Other Intangible Assets [Abstract]
2016 (three months remaining)	$ 858
2,017	3,270
2,018	3,270
2,019	3,270
2,020	$ 3,270

Other Intangible Assets (Deta58

Other Intangible Assets (Details Textuals) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Other Intangible Assets (Textuals) [Abstract]
Other Intangible Asset, comprised mainly of ERP System	$ 14		$ 14
Acquisition of other intangible assets, cost			$ 3.2
Weighted average amortization period for additions to other intangible assets			P10Y
Costs incurred to renew or extend the term of acquired other intangible assets	less than	less than		less than
Costs incurred to renew or extend the term of acquired other intangible assets	$ 0.1	$ 0.1	$ 0.2	$ 0.1

Credit Facility and Playa Vis59

Credit Facility and Playa Vista Loan (Details Textuals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Mar. 03, 2015	Oct. 06, 2014
Playa Vista Construction Loan [Member]
Credit Facility and Playa Vista Construction Loan (Textuals) [Abstract]
Playa Vista construction loan funding							$ 22,300
Interest rate description			Prior to the conversion, the Playa Vista Construction Loan bore interest at a variable interest rate per annum equal to 2.25% above the 30-day LIBOR rate, and PV Borrower was required to make monthly payments of interest only.
Effective interest rate		2.45%		2.44%
Playa Vista Loan [Member]
Credit Facility and Playa Vista Construction Loan (Textuals) [Abstract]
Maximum borrowing capacity	$ 30,000		$ 30,000
Amounts Drawn	$ 28,167		$ 28,167		$ 29,667
Playa Vista Construction Loan conversion date					Oct. 19, 2015
Additional borrowing under revolving term loan					$ 7,700
Interest rate description			As a result of the conversion, the interest rate decreased from 2.25% to 2.0% above the 30-day LIBOR rate
Total cost of development of the Playa Vista Project					54,000
Effective interest rate	2.51%		2.46%
Maturity date			Oct. 19, 2025
Term of loan			120 months
Playa Vista Loan - Payment Terms			PV Borrower will be required to make monthly payments of combined principal and interest over a 10-year term with a lump sum payment at the end of year 10. The Playa Vista Loan is being amortized over 15 years. The Playa Vista Loan will be fully due and payable on October 19, 2025.
Playa Vista Loan - Security			The Playa Vista Loan is secured by a deed of trust from PV Borrower in favor of Wells Fargo, granting a first lien on and security interest in the Playa Vista property and the Playa Vista Project, including all improvements to the constructed thereon, and other documents evidencing and securing the loan (the "Loan Documents").
Wells Fargo Foreign Exchange Facility [Member]
Credit Facility and Playa Vista Construction Loan (Textuals) [Abstract]
Settlement risk on its foreign currency forward contracts	$ 0		$ 0
Notional Amount of arrangements entered into	26,869		26,869
Bank of Montreal Facilities [Member]
Credit Facility and Playa Vista Construction Loan (Textuals) [Abstract]
Remaining Borrowing Capacity	10,000		10,000		10,000
Letters of credit and advance payment guarantees	100		$ 100		300
Credit Facility [Member]
Credit Facility and Playa Vista Construction Loan (Textuals) [Abstract]
Credit Facility Maturity Date			Mar. 3, 2020
Maximum borrowing capacity						$ 200,000
Remaining Borrowing Capacity	200,000		$ 200,000		200,000
Amounts Drawn	0		0		0
Letters of credit and advance payment guarantees	$ 0		$ 0		$ 0
Line of credit facility covenant terms			On February 22, 2016, the Company amended the terms of the Credit Agreement to increase the general restricted payment basket thereunder (which covers, among other things, the repurchase of shares) from $150 million to $350 million in the aggregate after the amendment date.
Compliance with covenants			The Company was in compliance with all of its requirements at September 30, 2016.

Contingencies and Guarantees 60

Contingencies and Guarantees (Details Textuals) - USD ($) $ in Millions	9 Months Ended	25 Months Ended	51 Months Ended	95 Months Ended
	Sep. 30, 2016	Dec. 14, 2015	Mar. 27, 2008	Dec. 02, 2011	Dec. 31, 2015
Final Award in favor of company			Amount of $11.3 million plus an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid	$30,000 to cover the costs of the application
Damages sought		$ 10.4
Counterclaim sought		$ 24
Financial Guarantees	$ 0
Indemnification of its directors/officers	$ 0				$ 0
Other Indemnification	0
Total amount payable related to customs audit	$ 3.4
Accrual recorded to costs and expenses applicable to revenue related to customs audit	0.8
Accrual recorded to Property, Plant and Equipment related to customs audit	0.8
Future input tax credits receivable	1.8
Net amount of VAT included in Accrued and other liabilities	$ 0

Condensed Consolidated Statem61

Condensed Consolidated Statements of Cash Flows Supplemental Information (Details 1) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Summary of Depreciation and amortization
Film assets	$ 11,842	$ 11,917
Property, plant and equipment
Joint revenue sharing arrangements	11,581	10,043
Other property, plant and equipment	7,355	5,635
Other intangible assets	2,368	2,354
Other assets	631	579
Deferred financing costs	402	663
Depreciation and amortization	$ 34,179	$ 31,191

Condensed Consolidated Statem62

Condensed Consolidated Statements of Cash Flows Supplemental Information (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Write-downs, net of recoveries
Accounts receivable			$ 556	$ 709
Financing receivables			75	0
Inventories	$ (15)	$ (59)	246	405
Film assets			1,000	0
Property, plant and equipment			792	1,464
Impairment of investments	$ 0	$ 0	194	350
Other intangible assets			40	0
Write-downs, net of recoveries			$ 2,903	$ 2,928

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Deferred Tax Assets
Deferred income tax asset after valuation allowance	$ 26.2	$ 26.2	$ 26.7
Deferred income tax asset before valuation allowance	26.5	26.5	27
Valuation allowance	0.3	0.3	$ 0.3
Excess tax benefit due to adoption of ASU 2016-09	$ 0	0.1
Deferred tax asset reclass due to adoption of ASU 2016-09		$ 0.9

Capital Stock (Details 2)

Capital Stock (Details 2) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Option activity under the Stock Option Plan and the IMAX LTIP
Options outstanding, end of period	5,473,673		5,473,673
Employee Stock Option [Member]
Option activity under the Stock Option Plan and the IMAX LTIP
Granted			984,452	871,431
Granted, weighted average exercise price per share			$ 31.49	$ 31.56
Exercised			(268,516)	(1,231,964)
Exercised, weighted average exercise price per share			$ 20.54	$ 19.35
Forfeited			(45,024)	(45,474)
Forfeited, weighted average exercise price per share			$ 28.03	$ 28.26
Cancelled	2,483	0	(2,483)	0
Cancelled, weighted average exercise price per share			$ 33.80	$ 0
Options outstanding, end of period	5,473,673	5,519,653	5,473,673	5,519,653
Options outstanding, weighted average exercise price per share, end of period	$ 28.14	$ 26.45	$ 28.14	$ 26.45
Options exercisable, end of period	3,924,432	3,195,836	3,924,432	3,195,836
Options exercisable, weighted average exercise price per share, end of period	$ 27.34	$ 25.14	$ 27.34	$ 25.14

Capital Stock (Details 3)

Capital Stock (Details 3) - Restricted Share Units (RSUs) [Member] - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Resticted Share Units activity under the IMAX LTIP
Granted	465,968	337,557
Granted, weighted average grant date fair value per share	$ 31.70	$ 34.39
Vested and settled	(271,032)	(192,077)
Vested and settled, weighted average grant date fair value per share	$ 29.30	$ 28.93
Forfeited	(28,435)	(19,499)
Forfeited, weighted average grant date fair value per share	$ 30.78	$ 29.37
RSUs outstanding, end of period	1,140,138	721,815
RSUs outstanding, weighted average grant date fair value per share, end of period	$ 32.78	$ 29.99

Capital Stock (Details 4)

Capital Stock (Details 4) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jan. 01, 2016	Dec. 31, 2015	Jun. 30, 2015	Jan. 01, 2015
Net income attributable to common shareholders	$ 2,525	$ 8,610	$ 19,843	$ 33,351
Less: Accretion charges associated with redeemable common stock	0	(263)	0	(747)
Net income applicable to common shareholders	$ 2,525	$ 8,347	$ 19,843	$ 32,604
Weighted average number of common shares:
Issued and outstanding, beginning of period	66,813,787		66,813,787		67,066,654	69,673,244	69,673,244	70,152,426	68,988,050
Weighted average number of shares issued (repurchased) during the period	23,128	(453,359)	(1,620,689)	594,029
Weighted average number of shares used in computing basic income per share	67,089,782	69,699,067	68,052,555	69,582,079
Assumed exercise of stock options and RSUs, net of shares assumed repurchased	656,438	1,161,385	668,325	1,519,785
Weighted average number of shares used in computing diluted income per share	67,746,220	70,860,452	68,720,880	71,101,864

Capital Stock (Details 5)

Capital Stock (Details 5) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Movement of Shareholders Equity
Balance as at December 31, 2015			$ 624,791
Net income attributable to common shareholders	$ 2,525	$ 8,610	19,843	$ 33,351
Adjustment to capital stock for cash received from issuance of common shares			5,514
Adjustment to capital stock for issuance of common shares for vested RSUs			1,121
Adjustment to capital stock for fair value of stock options exercised at the grant date			2,104
Adjustment to capital stock for average carrying value of repurchased and retired common shares	(21,220)		(21,220)
Adjustment to capital stock for shares held in treasury	(6)		(6)		$ 0
Adjustment to other equity for employee stock options granted			10,092
Adjustment to other equity for non-employee stock options granted and vested			30
Adjustment to other equity for fair value of stock options exercised at the grant date			(2,104)
Adjustment to other equity for RSUs granted	12,242		12,242
Adjustment to other equity for RSUs vested	(8,793)		(8,793)
Adjustment to other equity for stock exercised from treasury shares			(1,216)
Adjustment to other equity for cash received from the issuance of common shares in excess of par value	1,682		1,682
Adjustment to accumulated deficit for common shares repurchased and retired	(79,158)		(79,158)
Adjustment to accumulated other comprehensive loss for unrealized net gain from cash flow hedging instruments			1,865
Adjustment to accumulated other comprehensive loss for the realization of cash flow hedging net loss upon settlement			2,565
Adjustment to accumulated other comprehensive loss for foreign currency translation adjustments			(434)
Adjustment to accumulated other comprehensive loss for the amortization of actuarial loss on post retirement benefit plan	17	$ 0	51	$ 0
Adjustment to accumulated other comprehensive loss for tax effect of movement in other comprehensive income			(1,166)
Balance as at September 30, 2016	$ 567,803		$ 567,803

Capital Stock (Details Textual)

Capital Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				9 Months Ended			12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2015	Sep. 30, 2015	Sep. 30, 2016	Oct. 07, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Apr. 20, 2016	Jan. 01, 2016	Oct. 08, 2015	Jan. 01, 2015	Jun. 16, 2014
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 7,740			$ 4,300	$ 22,489		$ 14,900
Reserved common shares for future issuance	12,467,960	7,023,258	7,023,258		12,467,960			7,023,258
Options outstanding	5,473,673				5,473,673
Antidilutive shares issuable upon exercise of stock options and restricted share units	2,570,983			1,473,950	2,834,896		1,067,859
Details of the share repurchase program					On April 20, 2016, the Company’s board of directors approved an incremental $50 million increase to the share repurchase allowance, for an aggregate allowance of $200 million under the program. All other terms remain unchanged.				On June 16, 2014, the Company’s board of directors approved a new $150.0 million share repurchase program for shares of the Company’s common stock. Purchases under the program commenced during the third quarter of 2014. The share repurchase program expires on June 30, 2017. The repurchases may be made either in the open market or through private transactions, subject to market conditions, applicable legal requirements and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.
Stock Repurchase Program, Authorized Amount										$ 200,000				$ 150,000
Stock Repurchase Program Expiration Date					Jun. 30, 2017
Stock Repurchased And Retired During Period, Shares	500,000			1,000,000	3,290,512		1,000,000
Stock Acquired, Average Cost per Share	$ 29.32			$ 34.25	$ 30.48		$ 34.25
Payments For Repurchase Of Common Stock	$ 14,664			$ 34,279	$ 100,378		$ 34,279
Number of treasury shares held in trust for future settlement of share based awards					176
Value of treasury shares held in trust for future settlement of share based awards	6	$ 0	$ 0		$ 6			$ 0
Accumulated earnings relcass due to adoption of ASU 2016-09					4,400
Deferred tax asset reclass due to adoption of ASU 2016-09					900
Other equity reclass due to adoption of ASU 2016-09					5,300
Stock-based compensation expense recovery due to adoption of ASU 2016-09					2,700
Employee Stock Option [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	3,392			2,300	9,370		8,400
Tax benefits realized stock options	$ 900			$ 500	$ 2,400		$ 1,800
Options exercisable	3,924,432			3,195,836	3,924,432		3,195,836
Options outstanding	5,473,673			5,519,653	5,473,673		5,519,653				4,805,244		5,925,660
Options outstanding, weighted average exercise price	$ 28.14			$ 26.45	$ 28.14		$ 26.45				$ 27.03		$ 24.24
Granted					984,452		871,431
Weighted average fair value of options granted	$ 7.80			$ 0	$ 8.16		$ 8.07
Options exercisable intrinsic value	$ 9,723				$ 9,723
Cancelled	2,483			0	(2,483)		0
Weighted average remaining contractual life of exercisable option					3 years 10 months 24 days
Intrinsic value of options exercised	$ 482			$ 1,200	$ 3,200		$ 21,400
Options common shares were vested and exercisable	3,924,432				3,924,432
Options exercisable, weighted average exercise price per share, end of period	$ 27.34			$ 25.14	$ 27.34		$ 25.14
Weighted average exercise price of options forfieted					$ 28.03		$ 28.26
Antidilutive shares issuable upon exercise of stock options and restricted share units	2,551,453			1,473,950	2,551,453		1,006,325
Options Non Employees [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	less than			less than	less than
Share-based compensation costs recorded for the period	$ 100			$ 100	$ (100)		$ 100
Options exercisable	26,950			21,525	26,950		21,525
Options outstanding	28,750			39,500	28,750		39,500
Options outstanding, weighted average exercise price	$ 26.90			$ 26.78	$ 26.90		$ 26.78
Granted	0			0	0		0
Amount for stock options or rights included in accrued liabilities					less than			less than
Amount for stock options or rights included in accrued liabilities	$ 100	100	$ 100		$ 100			$ 100
Intrinsic value of options exercised	$ 100			$ 200	$ 100		$ 200
Options exercisable, weighted average exercise price per share, end of period	$ 26.97			$ 26.34	$ 26.97		$ 26.34
Employee Stock Option China Incentive Plan [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 200	2,100		$ 100	$ 700		$ 300	$ (600)
Options outstanding												186,446
Options outstanding, weighted average exercise price												$ 23.70
Granted								0
Options fully vested or expected to vest, weighted average remaining contractual life						7 years
Common share options subject to vesting based on performance commitment												186,446
Options forfeited			186,446
Weighted average exercise price of options forfieted			$ 23.70
Fair value of options outstanding												$ 1,900
Share-based compensation costs, not yet recognized, period for recognition						5 years
Total fair value of awards granted			$ 3,900
CSSBP [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	100	1,400			300
Granted								0
Amount for stock options or rights included in accrued liabilities	700	400	400		700			$ 400
Options vested and settled during period		$ 1,000
Total fair value of awards granted			$ 2,100
China RSU [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 100				$ 400
Restricted Share Units (RSUs) [Member]
Capital Stock (Textuals) [Abstract]
Number of RSUs outstanding	1,140,138			721,815	1,140,138		721,815				973,637		595,834
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period					465,968		337,557
RSUs outstanding, Weighted Average Grant Date Fair Value per Share	$ 32.78			$ 29.99	$ 32.78		$ 29.99				$ 32.27		$ 27.13
Antidilutive shares issuable upon exercise of stock options and restricted share units	19,530			0	283,443		61,534
Share-based compensation costs, not yet recognized, period for recognition					2 years 4 months 24 days		3 years
Share-based compensation costs, not yet recognized	$ 26,753			$ 16,400	$ 26,753		$ 16,400
Tax benefits realized	$ 300			$ 400	$ 2,600		$ 2,000
Restricted Stock Unit Contingent Right	1
Restricted Stock Unit Economic Equivalent	1
Common shares issued in connection with vested RSUs	27,416			32,345	271,032		192,077
Common shares issued from treasury in connection with vested RSUs	21,871			0	50,167		21,709
Common shares purchased in open market by trustee in connection with RSUs	217			26,582	212,029		164,387
Shares withheld for tax withholding	5,328			5,763	8,836		5,981
Number of treasury shares held in trust for future settlement of share based awards					176
Value of treasury shares held in trust for future settlement of share based awards	$ 6				$ 6
RSUs that may vest on shorter schedule					300,000
Restricted Share Units (RSUs) [Member] | Employee [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period	$ 3,900			$ 1,900	$ 11,600		$ 6,200
Common shares purchased in open market by trustee in connection with RSUs	0				249,657
Weighted average price of common shares purchased in open market by trustee in connection with RSUs	$ 0				$ 33.55
Restricted Share Units (RSUs) [Member] | Non Employee [Member]
Capital Stock (Textuals) [Abstract]
Share-based compensation costs recorded for the period				less than			less than
Share-based compensation costs recorded for the period	$ 0			$ 100	$ 0		$ 100
Maximum [Member] | Restricted Share Units (RSUs) [Member]
Capital Stock (Textuals) [Abstract]
Stock based awards vesting period					4 years		4 years
Minimum [Member] | Restricted Share Units (RSUs) [Member]
Capital Stock (Textuals) [Abstract]
Stock based awards vesting period					1 year		0 years

Segmented Information (Details

Segmented Information (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Geographical Information
Revenues, total	$ 86,550	$ 85,101	$ 270,421	$ 254,472
United States [Member]
Geographical Information
Revenues, total	28,139	27,914	96,276	95,945
Canada [Member]
Geographical Information
Revenues, total	2,368	3,412	9,992	8,440
Greater China [Member]
Geographical Information
Revenues, total	29,736	27,513	84,797	71,427
Asia (excluding Greater China) [Member]
Geographical Information
Revenues, total	10,665	11,007	25,034	26,732
Western Europe [Member]
Geographical Information
Revenues, total	6,140	7,100	26,522	24,139
Russia & the CIS [Member]
Geographical Information
Revenues, total	2,397	1,705	7,684	9,510
Latin America [Member]
Geographical Information
Revenues, total	1,408	2,459	8,562	7,849
Rest of the World [Member]
Geographical Information
Revenues, total	$ 5,697	$ 3,991	$ 11,554	$ 10,430

Segmented Information (Detail70

Segmented Information (Details Textual) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)Segments	Sep. 30, 2015USD ($)
Segment Reporting (Textuals) [Abstract]
Number of Reportable Segments | Segments			7
Marketing and commission costs	$ 1.3	$ 1.3	$ 3	$ 2.8
Disclosure on Geographic Areas, Description of Revenue from External Customers			No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) classifications comprise more than 10% of total revenue.
Description of products and services from which each reportable segment derives its revenues			The Company has seven reportable segments identified by category of product sold or service provided: IMAX systems; theater system maintenance; joint revenue sharing arrangements; film production and IMAX DMR; film distribution; film post-production; and other. The IMAX systems segment designs, manufactures, sells or leases IMAX theater projection system equipment. The theater system maintenance segment maintains IMAX theater projection system equipment in the IMAX theater network. The joint revenue sharing arrangements segment provides IMAX theater projection system equipment to an exhibitor in exchange for a share of the box-office and concession revenues. The film production and IMAX DMR segment produces films and performs film re-mastering services. The film distribution segment distributes films for which the Company has distribution rights. The film post-production segment provides film post-production and film print services. The other segment includes certain IMAX theaters that the Company owns and operates, camera rentals and other miscellaneous items.
Description of the basis of accounting for transactions between reportable segments			The accounting policies of the segments are the same as those described in note 2 to the audited consolidated financial statements included in the Company's 2015 Form 10-K. Transactions between the film production and IMAX DMR segment and the film post-production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below.
IMAX systems [Member]
Segment Reporting (Textuals) [Abstract]
Advertising, marketing and commission costs	0.8	0.9	$ 1.9	1.8
Joint revenue sharing arrangements [Member]
Segment Reporting (Textuals) [Abstract]
Advertising, marketing and commission costs	1.4	1.3	2.9	2.7
Production and IMAX DMR [Member]
Segment Reporting (Textuals) [Abstract]
Marketing costs (recovery)	4.2	$ 3.4	11.7	8.3
Distribution [Member]
Segment Reporting (Textuals) [Abstract]
Marketing costs (recovery)		less than
Marketing costs (recovery)	$ 0.6	$ (0.1)	$ 2.1	$ (0.1)
Significant Customer 1 [Member]
Segment Reporting (Textuals) [Abstract]
Percentage of total revenues represented by largest customer	11.20%	17.60%	14.30%	17.40%

Employees Pension and Postret71

Employees Pension and Postretirement Benefits (Details 1) $ in Thousands	Sep. 30, 2016USD ($)
SERP Benefits [Member]
Schedule of expected benefit payments
2016 (three months remaining)	$ 0
2,017	19,871
2,018	0
2,019	0
2,020	0
Thereafter	0
Total expected future benefit payment	19,871
Postretirement Benefits Executives [Member]
Schedule of expected benefit payments
2016 (three months remaining)	34
2,017	54
2,018	60
2,019	66
2,020	33
Thereafter	539
Total expected future benefit payment	786
Postretirement Benefits Canadian Employees [Member]
Schedule of expected benefit payments
2016 (three months remaining)	96
2,017	100
2,018	108
2,019	115
2,020	117
Thereafter	1,330
Total expected future benefit payment	$ 1,866

Employees Pension and Postret72

Employees Pension and Postretirement Benefits (Details Textuals) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Employees Pension and Postretirement Benefits (Additional Textuals) [Abstract]
Description Of Defined Contribution Pension And Other Postretirement Plans			The Company also maintains defined contribution pension plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums.
Maximum percentage of base salary contributed to Defined Contribution Pension Plan by Company			5.00%
SERP Benefits [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Accumulated benefit obligation for the SERP	$ 19,700		$ 19,700		$ 19,500
Benefit Obligation	19,674		19,674		19,478	$ 19,405
Companies contribution and expenses			0
Expected interest costs in the remainder of the year	100		100
Postretirement Benefits Executives [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Benefit Obligation	$ 786		$ 786		763
Maximum amount of Postretirement benefit expensed	less than	less than	less than	less than
Maximum amount of Postretirement benefit expensed	$ 100	$ 100	$ 100	$ 100
Postretirement Benefits Canadian Employees [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Benefit Obligation	$ 1,866		$ 1,866		$ 1,778
Maximum amount of Postretirement benefit expensed	less than	less than	less than
Maximum amount of Postretirement benefit expensed	$ 100	$ 100	$ 100	100
Canadian Plan [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Companies contribution and expenses	316	245	891	819
U.S. Internal Revenue Code [Member]
Pension and Other Postretirement Benefit Expense (Textuals) [Abstract]
Companies contribution and expenses	$ 137	$ 200	$ 486	$ 400

Financial Instruments (Details

Financial Instruments (Details 2) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	$ 9,515	$ 11,617
Financed Sales Receivables	110,697	106,854
Total	120,212	118,471
In Good Standing [Member]
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	7,974	10,252
Financed Sales Receivables	108,375	105,352
Total	116,349	115,604
Pre-Approved Transactions [Member]
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	0	0
Financed Sales Receivables	1,387	757
Total	1,387	757
Transactions Suspended [Member]
Recorded investment in financing receivables by credit quality indicator
Minimum Lease Payments	1,541	1,365
Financed Sales Receivables	935	745
Total	$ 2,476	$ 2,110

Financial Instruments (Detail74

Financial Instruments (Details 3) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Investment In Financing Receivables On Nonaccrual Status
Net investment in leases recorded investment	$ 1,541	$ 1,365
Net investment in leases related allowance	(672)	(672)
Net financed sales receivables recorded investment	935	745
Net financed sales receivables related allowance	(643)	(568)
Total recorded investment	2,476	2,110
Total related allowance	$ (1,315)	$ (1,240)

Financial Instruments (Detail75

Financial Instruments (Details 4) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Jan. 01, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Jan. 01, 2015
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	$ 6,346			$ 4,561
Related Unbilled Recorded Investment	113,866			113,910
Total Recorded Investment	120,212			118,471
Related Allowances	(1,315)			(1,240)
Recorded Investment Net of Allowances	118,897			117,231
Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,122			1,748
Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	964			1,190
Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	3,260			1,623
Net Investment in Leases [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	936			1,463
Related Unbilled Recorded Investment	8,579			10,154
Total Recorded Investment	9,515			11,617
Related Allowances	(672)	$ (672)	$ (672)	(672)	$ (972)	$ (972)	$ (972)
Recorded Investment Net of Allowances	8,843			10,945
Net Investment in Leases [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	84			840
Net Investment in Leases [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	81			177
Net Investment in Leases [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	771			446
Net Financed Sales Receivables [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	5,410			3,098
Related Unbilled Recorded Investment	105,287			103,756
Total Recorded Investment	110,697			106,854
Related Allowances	(643)	$ (643)	$ (568)	(568)	$ (494)	$ (494)	$ (494)
Recorded Investment Net of Allowances	110,054			106,286
Net Financed Sales Receivables [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,038			908
Net Financed Sales Receivables [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	883			1,013
Net Financed Sales Receivables [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,489			1,177
Financing Receivables Continue To Accrue Finance Income [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	3,911			1,485
Related Unbilled Recorded Investment	25,527			11,871
Related Allowances	0			0
Recorded Investment Net of Allowances	29,438			13,356
Financing Receivables Continue To Accrue Finance Income [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	558			170
Financing Receivables Continue To Accrue Finance Income [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	575			271
Financing Receivables Continue To Accrue Finance Income [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	2,778			1,044
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	380			293
Related Unbilled Recorded Investment	2,424			1,076
Related Allowances	0			0
Recorded Investment Net of Allowances	2,804			1,369
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	12			41
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	53			47
Financing Receivables Continue To Accrue Finance Income [Member] | Net Investment in Leases [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	315			205
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	3,531			1,192
Related Unbilled Recorded Investment	23,103			10,795
Related Allowances	0			0
Recorded Investment Net of Allowances	26,634			11,987
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Financing Receivables Accrued and Current
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	546			129
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Financing Receivables 30 to 89 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	522			224
Financing Receivables Continue To Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Financing Receivables Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable, Recorded Investment, Past Due [Line Items]
Billed Financing Receivables	$ 2,463			$ 839

Financial Instruments (Detail76

Financial Instruments (Details 5) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Financing Receivable, Impaired [Line Items]
Recorded Investment	$ 748	$ 525	$ 748	$ 525
Unpaid Principal	269	53	269	53
Related Allowance	(643)	(494)	(643)	(494)
Average Recorded Investment	748	525	674	525
Interest Income Recognized	0	0	0	0
Net Financed Sales Receivables [Member]
Financing Receivable, Impaired [Line Items]
Impaired Financing Receivable with Related Allowance, Recorded Investment	748	525	748	525
Impaired Financing Receivable With Related Allowance, Unpaid Principal	269	53	269	53
Impaired Financing Receivable With Related Allowance, Average Recorded Investment	748	525	674	525
Impaired Financing Receivable With Related Allowance, Interest Income Recognized	0	0	0	0
Impaired Financing Receivable With No Related Allowance, Recorded Investment	0	0	0	0
Impaired Financing Receivable With No Related Allowance, Unpaid Principal	0	0	0	0
Impaired Financing Receivable With No Related Allowance, Average Recorded Investment	0	0	0	0
Impaired Financing Receivable With No Related Allowance, Interest Income Recognized	0	0	0	0
Related Allowance	$ (643)	$ (494)	$ (643)	$ (494)

Financial Instruments (Detail 6

Financial Instruments (Detail 6) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Allowance for credit losses:
Beginning balance			$ 1,240
Ending balance	$ 1,315		1,315
Net Investment in Leases [Member]
Allowance for credit losses:
Beginning balance	672	$ 972	672
Charge-offs	0	0	0	$ 0
Recoveries	0	0	0	0
Provision	0	0	0	0
Ending balance	672	972	672	972
Ending balance: individually evaluated for impairment	672	972	672	972
Financing receivables:
Ending balance: individually evaluated for impairment	9,515	12,032	9,515	12,032
Net Financed Sales Receivables [Member]
Allowance for credit losses:
Beginning balance	643	494	568
Charge-offs	0	0	0	0
Recoveries	0	0	0	0
Provision	0	0	75	0
Ending balance	643	494	643	494
Ending balance: individually evaluated for impairment	643	494	643	494
Financing receivables:
Ending balance: individually evaluated for impairment	$ 110,697	$ 103,418	$ 110,697	$ 103,418

Financial Instruments (Detail78

Financial Instruments (Details 7) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts - Forwards	$ 26,869	$ 30,710

Financial Instruments (Detail79

Financial Instruments (Details 8) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair value of foreign exchange contracts
Foreign exchange contracts - designated forwards	$ 7	$ (4,423)
Other Assets [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]
Fair value of foreign exchange contracts
Derivative Asset, Fair Value	734	0
Accrued and other liabilities [Member] | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]
Fair value of foreign exchange contracts
Derivative Liability, Fair Value	$ (727)	$ (4,423)

Financial Instruments (Detail80

Financial Instruments (Details 9) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Derivatives in Foreign Currency Hedging relationships
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	$ (293)	$ (2,309)	$ 1,865	$ (4,983)
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)	(572)	(1,045)	(2,565)	(2,196)
Selling, general and administrative expenses [Member]
Derivatives in Foreign Currency Hedging relationships
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)	(572)	(1,045)	(2,565)	(2,196)
Fair Value Hedging [Member]
Derivatives in Foreign Currency Hedging relationships
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	$ (293)	$ (2,309)	$ 1,865	$ (4,983)

Financial Instruments (Detail81

Financial Instruments (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Financial Instruments (Textuals) [Abstract]
Transfers into/out of Level 3			$ 0	$ 0
Financing receivables indications of theaters with potential collection concerns			60-89 days
Financing receivables indications of theaters to review and assess			Once a theater’s aging exceeds 90 days, the Company’s policy is to review and assess collectibility on the theat
Financing receivables indications of theaters with potential impairment			Over 90 days past due is used by the Company as an indicator of potential impairment as invoices up to 90 days outstanding could be considered reasonable due to the time required for dispute resolution or for the provision of further information or supporting documentation to the customer
Estimated gain to be reclassified to earnings within the next twelve months			$ 100
Financial Instruments Additional (Textuals) [Abstract]
Carrying value of investments accounted for under the equity method of accounting	$ 1,000		1,000		$ 2,200
Adjustment directly to earnings for impairment of available-for-sale investment	0	$ 0	194	350
Convertible loan receivable	1,000		$ 1,000
Convertible loan effective interest rate			5.00%
Convertible loan receivable due date			Sep. 26, 2019
Schedule of Available For Sale Securities [Line Items]
Investment classified as available-for-sale - cost	1,500		$ 1,500
Investment classified as available-for-sale - fair value	0		0		0
Variable Interest Entity, Not Primary Beneficiary [Member]
Financial Instruments Additional (Textuals) [Abstract]
Carrying value of investments accounted for under the equity method of accounting	0		0		1,000
Equity method investment, difference between carrying amount and underlying equity	1,400		1,400
Variable Interest Entity, Not Primary Beneficiary [Member] | Equity Accounted Investment [Member]
Financial Instruments Additional (Textuals) [Abstract]
Gross revenues of investment new business ventures	0	0	300	0
Cost of revenue of investment new business ventures	1,600	1,900	6,000	6,400
Net loss on equity-accounted investments	1,500	$ 1,800	5,600	$ 6,200
Other Debt Securities [Member]
Schedule of Available For Sale Securities [Line Items]
Investment classified as available-for-sale - cost	2,500		2,500
Fixed Income Securities [Member]
Schedule of Available For Sale Securities [Line Items]
Investment classified as available-for-sale - cost	$ 1,000		$ 1,000		$ 1,000

Non-Controlling Interests (De82

Non-Controlling Interests (Details Textuals) $ in Thousands	Feb. 10, 2015USD ($)	Apr. 08, 2014USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2014USD ($)yrFilm
Redeemable Noncontrolling Interest [Line Items]
Aggregate subscription price			$ 0	$ 40,000
Investment in film assets			$ (14,162)	$ (12,069)
IMAX China Noncontrolling Interest
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interest description		On April 8, 2014, the Company announced the sale and issuance of 20.0% of the shares in IMAX China to entities owned and controlled by CMC Capital Partners ("CMC"), an investment fund focused on media and entertainment, and FountainVest Partners ("FountainVest"), a China-focused private equity firm.
Minority Interest Ownership Percentage By Company			68.50%
Minority Interest Ownership Percentage By Noncontrolling Owners		20.00%
IMAX China Noncontrolling Interest | Class C Shares [Member]
Redeemable Noncontrolling Interest [Line Items]
Aggregate subscription price	$ 40,000	$ 40,000
Other Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interest description					In 2014, the Company announced the creation of the Film Fund to co-finance a portfolio of 10 original large-format films. The Film Fund, which is intended to be capitalized with up to $50.0 million, will finance an ongoing supply of original films that the Company believes will be more exciting and compelling than traditional documentaries. The initial investment in the Film Fund was committed to by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company, which will contribute $9.0 million to the Film Fund over five years starting in 2014, anticipates the Film Fund will be self-perpetuating, with a portion of box office proceeds reinvested into the Film Fund to generate a continuous, steady flow of high-quality documentary content. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, title and interest in the co-financed pictures.
Number Of Expected Original Films | Film					10
Film Fund Expected Capital Contribution					$ 50,000
Investment in film assets			$ 7,700
Other Noncontrolling Interest [Member] | Third Party [Member]
Redeemable Noncontrolling Interest [Line Items]
Film Fund commitment amount					25,000
Other Noncontrolling Interest [Member] | IMAX [Member]
Redeemable Noncontrolling Interest [Line Items]
Film Fund commitment amount					$ 9,000
Contribution Period | yr					5